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Abstract 
 
Ghadiri reported the first synthetic peptide nanotubue in 1993, which has triggered 
extensive studies on peptide-based nanotubes and their potential application in molecular 
wires, catalysts and novel drug delivery vehicles. Our concerns focus on chromophore-
modified cyclic peptides, which open a new way to design and synthesize novel 
nanoscale electronic or photonic devices, and are expected to provide the highly efficient 
electron and energy transfer that such devices require. 
This research concerned the design and synthesis of chiral α-amino acids with specific 
chromophores, including N-ethyl-3-carbazolylalanine and 9-anthrylalanine, and an 8-mer 
linear peptide (H-Aib-Car-Aib-Phe-Aib-Bpa-Aib-Phe-OH) and its corresponding cyclic 
peptide cyclo(Aib-Car-Aib-Phe-Aib-Bpa-Aib-Phe) that incorporate the N-ethyl-3-
carbazolylalanine. This thesis describes the relevant background, synthetic strategies, 
experiments and results in detail. 
The carbazole derivatives were found to be very labile to strong acid, which might 
have caused self-condensation. In order to avoid the formation of acid-derived side-
products, the Wittig-Horner reaction was used successfully in preparation of N-protected-
3-(N’-ethyl-3-carbazolyl)-DL-alanine methyl ester. Dual enzymatic hydrolyses were 
developed to produce the chiral amino acids with high enantiomeric excess. ChiroCLEC-
BL was used to selectively hydrolyze the N-acetyl-L-amino acid methyl ester, while 
amanoacylase was adopted to remove the acetyl group from the resulting N-acetyl-L-
amino acid. 
 ii 
Two model peptides were synthesized, a 4-mer peptide (H-Car-D-Ala-Bpa-D-Ala-
OH) via the Boc-strategy, and an 8-mer peptide (H-D-Ala-Npa-D-MeAla-Ala-D-Ala-
Bpa-D-Ala-Ala-OH) by the Fmoc-strategy. Eventually, the target linear peptide was 
synthesized via the Fmoc-strategy and then cyclized in solution. 
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Chapter 1   Introduction 
 
1. 1 Research goal 
One fundamental goal of our laboratory is to design and synthesize bichromophore-
containing cyclic peptides, and to explore their self-assembly into peptide-based 
nanotubes. If successful, it would open a new way to self-assemble novel nanoscale 
electronic or photonic devices. It is anticipated that such structures could be applied in a 
high-resolution display. The building units would transmit information via highly 
efficient intramolecular energy transfer between the chromophores. 
This research concerned the design and synthesis of chiral α-amino acids with specific 
chromophores, incorporating them into a bichromophoric linear 8-mer peptide, and 
cyclizing the linear peptide. The cyclic peptides will be used to investigate photoinduced 
intramolecular energy transfer between the chromophores in order to further develop 
novel molecular devices in the near future. 
 
1. 2 Peptide based nanotubes 
With the fast-increasing demand for high-speed electronic devices, e.g. molecular 
computers, molecular nanotechnology featuring the miniaturization of physical 
components of devices has made great progress in designing and controlling organic 
molecules and carbon nanotubes in the past decade.1 
 2 
Chemists obtained great inspiration from the way that biological systems create life 
and self-assemble the supramolecular structures into the living units, and began to 
explore artificial approaches to intelligent functional supramolecular materials.2 The 
artificial peptide-based nanotube was a successful landmark.3 
 
 
Figure 1-1   A cyclic peptide, cyclo[-(D-Ala-Glu-D-Ala-Gln)2-] and the nanotubes formed by its self-
assembly.1 
 
In nature, many peptide and protein-based microtubules build their sub-cellular 
structure by self-assembly techniques. In 1993, the Ghadiri group reported the first 
synthetic peptide nanotube (Figure1-1). The cyclic peptide cyclo[-(D-Ala-Glu-D-Ala-
Gln)2-] with an even number of alternating D- or L-amino acids, which favors a low-
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energy flat conformation, was used as the molecular building block of the nanotubes. All 
the side chains of the amino acids are allowed to point outwards. The amide backbone 
forms hydrogen bonds in a direction perpendicular to the plane of the cyclic peptide. 
When two cyclic peptides stack upon one another, a hydrogen-bonding network is 
formed, which looks like a contiguous, anti-parallel β sheet, commonly found in natural 
proteins. As this hydrogen-bonded lattice propagates in a direction perpendicular to the 
plane of the cyclic peptide, a highly ordered parallel array of nanotubular structure with 
fixable internal diameter and modifiable exterior surface is formed by self-assembly. 
Hundreds of these nanotubes are tightly packed to form crystalline fibers.1 
This nanotube used a pH triggered self-assembly mechanism. The protonation of two 
glutamic acid residues was designed as the switch. At high or neutral pH, the cyclic 
peptide has a negative charge and is water-soluble, and the repulsive charges on the 
cyclic peptides resist the amide backbone hydrogen bonding. When the pH is lowered, 
the glutamic acids are protonated and the solubility decreases. In the meantime, the 
repulsive charges are removed, which induces amide backbone hydrogen bonding and 
self-assembly into tubular microcrystals with a diameter of 7.5 Å. When the number of 
amino acid residues making up of the cyclic peptide is increased from eight to twelve, 
another large-size microcrystalline nanotube (cyclo[-(D-Ala-Glu-D-Ala-Gln)3-]) is 
formed with a 13 Å diameter, which displays greater stability in a broad range of pHs and 
solvents.4 
Another group of nanotubes designed by the Ghadiri group adopted a highly 
hydrophobic outer surface and hydrophilic inner pore, such as cyclo[-(Phe-D-MeNAla-
Hag-D-MeNAla)2-] (Hag represents homoallylglycine)5 and cyclo[-(Trp-D-Leu)3-Gln-D-
 4 
Leu].6 Such nanotubes are easily inserted into a lipid bilayer. Some ions were found to be 
able to pass through the open ends of the nanotubes, which would allow new applications 
as highly efficient ion channels. Nanotubes with slightly larger pores have been shown to 
transport small molecules, such as glucose.7 
The theoretical and applied studies on peptide-based nanotubes have attracted the 
attention of many research labs.8,9 Based on the experimental results, Lewis calculated 
the energetics, electronic structure and vibrational spectra of cyclo[-(D-Ala-Glu-D-Ala-
Gln)m=1-4].10 Such research could provide the theoretical guide for future work on 
computer-aided molecular design of peptide nanotube-based molecular devices. By 
adjusting the number and choice of the amino acid residues, the cyclic peptide nanotubes 
can be designed with desirable surface characteristics and pore sizes. They can be easily 
synthesized by combining self-assembly with standard solid phase peptide synthesis. 
The potential applications of peptide-based nanotubes cover nanowires, optical and 
electronic devices, catalytic media, therapeutic agents, transmembrane channels, and 
novel drug delivery systems.1 
 
1. 3 Why did we consider cyclic peptides as investigative candidates? 
Research on photoinduced intramolecular energy and charge transfer in 
polychromophoric helical peptides composed of various numbers of unnatural amino acid 
residues carrying the chromophores on the peptide backbone has been undertaken.11,12,13 
The research has been concerned mainly with varying the distance between 
chromophores, devising less complicated means of incorporating various chromophores 
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into the peptide, and forming the secondary helical structure to limit the change of 
conformation. 
Our latest task with chromophore-modified cyclic peptides is made easier by their 
tendency to self-assemble into peptide nanotubes. At the same time, photochemical 
research on the chromophore-modified cyclic peptide nanotube is an unexplored field as 
yet. There are a couple of factors that led us into this research. 
• The cyclic peptide adopts a stable conformation that facilitates unidirectional, 
highly efficient energy transfer in molecular devices. 
• Automatic solid-phase peptide synthesis can be utilized to simplify synthesis and 
purification. 
• Flexible adjustments of the distance between the chromophores can be made by 
changing their attachment positions and the internal diameter of the cycle peptide. 
• The property of the exterior surface can be controlled by changing the 
chromophores. 
• Favorable self-assembly creates nanoscale devices. The intermolecular hydrogen 
bonding and ring stacking interactions of peptide subunits in the β conformation 
would be energetically favored under appropriate conditions, and would thus 
produce open-ended, hollow, tubular ensembles. 
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1. 4 Photoinduced intramolecular energy transfer between 
chromophores14 
There are two important mechanisms that theoretically describe the photoinduced 
intramolecular energy transfers, the Förster mechanism and the Dexter mechanism 
(Figure 1-2). 
D* D*A*
LUMO
Forster MechanismDexter Mechanism
ET ET
DA A
HOMO
 
 
Figure 1-2   Photoinduced energy transfer pathways. D represents the donor; A represents the acceptor; the 
horizontal line means a molecular orbital; a dot stands for an electron, and * indicates an excited state. 
 
The Dexter mechanism is based on electron exchange. It occurs when one electron 
moves from the LUMO of the donor to a LUMO of the acceptor, while at the same time, 
another electron is exchanged from HOMO of the acceptor to one of the donor. As a 
result, the excited-state donor returns to the ground state while the acceptor is excited. A 
through-bond pathway is effective over a range of 10-15 Å. A through-space path is also 
available if there is good overlap of the acceptor and donor orbitals. 
The Förster mechanism is based on an electrodynamic interaction between the donor 
and acceptor. The oscillating donor dipole in the excited state induces oscillation of the 
acceptor dipole. This through-space mechanism is effective over many tens of Å. Singlet-
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singlet energy transfer (SSET) is viable via this mechanism, while triplet-triplet energy 
transfer (TTET) is forbidden here. 
There are three chromophores - anthracene, benzophenone and N-ethylcarbazole - that 
we considered for incorporation into cyclic peptides, based on preliminary photophysical 
investigations.15,16 The α-alanine skeleton would be used as a spacer, with the 
chromophore attached to C-3. An energy diagram illustrating the predicted pathways of 
intramolecular energy transfer is shown in Figure 1-3. Carbazole has the highest first 
excited singlet energy level (S1) and first triplet energy level (T1), while anthrance has the 
lowest S1 and T1. Carbazole will always act as a donor, while anthracene will always be 
an acceptor. Both singlet–singlet energy transfer (SSET) and triplet-triplet energy transfer 
(TTET) will be expected to occur. Benzophenone can act as the donor to anthrance or the 
acceptor from carbazole. Interestingly, benzophenone and carbazole have the same T1 
energy. Thus highly efficient reversible TTET would be expected. 
We planned to attach two of these chromophores to the 8-mer linear and cyclic peptide 
scaffolds, and then observe the energy transfer efficiency. In the first instance, two 
chromophores would be separated by three other amino acid residues. 
 
1. 5 Synthesis of optically active α-amino acid 
The design and synthesis of novel, unnatural, optically active α-amino acids have 
generated interest due to their potential in improvement of pharmacological and chemical 
applications and their flexibility in incorporation into synthetic peptides.17,18 With the 
different chromophores attached to the β-carbon of the amino acids, these derivatives 
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would provide specific photophysical and photochemical properties. 
 
N
Et
N
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O
T1
T1 T1 T1
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SSET
TTET
SSET
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Figure 1-3   Energy diagram for intramolecular energy transfer among the proposed chromophores (broken 
dashed arrows show possible pathways of energy transfer). 
 
1. 5. 1 Building the α-amino acid skeleton 
There are several methods that have been used to build the amino acid skeleton. 
 
• Sorensen method19 
The Sorensen method starts with alkylation of N-acetylaminomalonic ester by an alkyl 
halide, using a strong base as deprotonating reagent. The diester product is hydrolyzed 
and decarboxylated to give the N-protected α-amino acid (Figure 1-4). Sisido made 3-(9-
anthryl)-DL-alanine via this way, 20 while Morrison prepared 3-(2-fluorenyl)-DL-alanine 
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following the same procedure.21 
 
OEt
OEt
NH
O
OO
Me
H RCH2
OEt
OEt
NH
O
OO
Me
RCH2Cl
HO
H
NH
O
O
Me
CH2RNa, EtOH 1. NaOH (4eq), EtOH
2. HCl
 
Figure 1-4   General pathway for the Sorensen method to make the α-amino acid derivatives. 
 
• Erlenmeyer’s azlactone method19,22 
Erlenmeyer’s azlactone synthesis is based on the Perkin reaction. First, an acylglycine 
is converted into an azlactone by the dehydration of its enol tautomer with Ac2O. The 
azlactone, whose methylene group is activated, undergoes Perkin condensation with the 
aldehyde. This product is then reduced and hydrolyzed to give an α-amino acid (Figure 
1-5). Taku reported the preparation of 3-(N-ethyl-3-carbazolyl)-DL-alanine by this 
method.23 
 
RCHO
H
N C
OH
O
O
Ph RCH
O
N Ph
O
NH
C
C
CH2R
HO O
Ph
O
H
+ 1. NaOH, EtOH
2. H2, Pd-C
Ac2O, NaOAc
reflux
 
Figure 1-5   General pathway for Erlenmeyer’s azlactone synthesis of the α-amino acid derivatives. 
 
• Wittig-Horner synthesis24 
The Wittig-Horner reaction occurs via condensation between phosphonate anions and 
aldehydes, and has been extensively used to synthesize dehydroamino acids, with a 
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preference for forming the Z-isomer (Figure 1-6). The reaction is carried out under mild 
conditions, especially suitable for sensitive chromophores, such as our substrates, the 
carbazolyl derivatives. Their syntheses will be discussed later. 
ArCHO
P
O
OMe
OMeNH
O
MeO H
Me
O
O
CHAr
HN
C
C
OMe
O
Me NHAC
C
OMe
O
H
Ar
+
tetramethylguanidine, THF H2 , Pd-C
-70 °C to rt
 
Figure 1-6   General pathway for Wittig-Horner reaction used to build the α-amino acid derivatives (Z may 
be Me, O-t-Bu or Cbz groups). 
 
• Strecker synthesis25 
The Strecker synthesis, a traditional approach to making unprotected racemic amino 
R
CN
H R
COOH
H
RCHO  +  NH3  +   HCN
H3O+
(a)
NH2 NH2
 
Ph H
N
PO Ph
Ph
PO
Ph
Ph
O
O
AlCl
H
Ph
CN
N
H
Ph
NH2H
COOH
, TMSCN, PhOH
1.
2. 2M HCl
       
         66-97%, 70-96% ee
1. HCl (g), HCOOH
2. DDQ
3. 1M HCl
4. Amberlyst A-21, MeOH
        91%, 98% ee (R=Ph) (b)
 
 
Figure 1-7   (a) General pathway for the traditional Strecker synthesis of  α-amino acid derivatives; 
                     (b) asymmetric Strecker-type synthesis of D-phenylalanine. 
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acids, involves treatment of aldehydes with hydrogen cyanide and ammonia. The 
intermediate α-aminonitrile is hydrolyzed with H3O+ to provide an α-amino acid (Figure 
1-7a). Recently, attention has turned to the catalytic asymmetric Strecker-type synthesis, 
which provides a direct method for asymmetric synthesis of α-amino acid derivatives 
(Figure 1-7b). 
 
• Alkylation of glycinate imines under phase transfer conditions26 
In 1989, O’ Donnell reported the catalytic enantioselective alkylation of the 
benzophenone imine of a glycine alkyl ester by pseudoenantiomeric phase transfer 
catalysis, to give enantiomerically enriched α-amino acids (Figure 1-8). Further 
recrystallization or enzymatic resolution was required to obtain a highly optically pure 
isomer. 
 
N
N+
OR
Cl-
Ph2=N CO2But
COOH
H
Cl
2) crystallize racemate
3) deprotect
1) 4-Cl-C6H4CH2Br, NaOH, CH2Cl2,
NH2
 
Figure 1-8   Catalytic enantioselective alkylation of glycinate imine under phase transfer catalysis. 
 
• Asymmetric hydrogenation27 
Asymmetric hydrogenation of dehydroamino acids using transition metal complexes 
with chiral ligands (e.g., BICPO) has provided an extremely useful approach to making a 
 12 
variety of optically active amino acids, e.g., N-acetyl-3-(2-naphthyl)-(R or S)-alanine 
methyl ester (Figure 1-9). 
 
NHR
CO2Me
CO2Me
H NHR(Rh(COD)2)BF4, (1R, 1'R, 2S, 2'S)-BICPO
H
Ph2PO
H
Ph2PO
(1R, 1'R, 2S, 2'S)-BICPO
H2
 
Figure 1-9   Rh-catalyzed asymmetric hydrogenation of an acetamidocinnamic ester. 
 
However, for bulky substrates such as these containing 9-anthryl and N-
ethylcarbazolyl side groups, there is no effective catalyst reported that can produce high 
enantiomeric excesses. The expensive chiral ligands also decreased our desire for 
attempting to find the optimal chiral ligand for our substrates. 
Asymmetric syntheses can build chiral amino acids directly with the aid of various 
chiral auxiliary reagents. The attainable enantiometric excess is in the range of 70-98%, 
but is heavily dependent on the stereochemical characteristics of the substrate and chiral 
reagents. In order to secure high enantiometric excess, enzymatic resolution seemed to us 
the most promising. 
1. 5. 2 Enzymatic resolution 
Enantiomers have identical physical and chemical properties, and so can’t be resolved 
by conventional methods, such as crystallization and standard chromatography. 
Traditionally, the enantiomers have been separated by converting them into 
 13 
diastereomeric salts. The salts can be isolated by crystallization or chromatography and 
then decomposed into the pure enantiomers. 
Our interest focused on enzymatic resolution. One isomer of the racemate is 
preferentially transformed into its hydrolytic product under enzymatic catalysis. The 
major approaches include stereospecific cleavage of N-acyl groups by acylases, and 
stereospcific ester hydrolysis by proteases. 
 
• Ester hydrolysis catalyzed by esterases17 
A practical resolution of racemic amino acid esters has been obtained using protease 
VIII (Figure 1-10). The L-methyl (or benzyl) ester can be enantiospecifically hydrolyzed 
in pH 8 buffer. It was noted that the benzyl ester is hydrolyzed three times faster than the 
corresponding methyl ester. It is important to monitor the reaction and stop it when it 
reaches 50% conversion. Organic co-solvents such as DMF, dioxane and CH3CN (up to 
30% v/v) do not significantly lower the enzyme activity, while enhancing the solubility of 
the substrates. The major advantages of this method are enzyme stability and ease of 
product isolation. The resultant enantiomeric excess and hydrolytic yield depend heavily 
on the structure of the substrate and the hydrolytic conditions. 
 
C
OMe
O
CH2ArH
AcNH AcNH
C
C
OH
O
CH2ArH
ArCH2
C C
OMe
O
H
protease VIII
+
AcNH
 
Figure 1-10   General pathway for enantiospecific ester hydrolysis by protease VIII. 
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The protease subtilisin is broadly applied in stereospecific ester hydrolyses. Its 
disadvantages are its low stability in water and water-miscible organics, and low activity 
in neat organic solvents, which limit its application. 
Subtilisin ChiroCLEC-BL is a crosslinked, crystalline subtilisin.28 Crosslinking 
confers high stability and activity at elevated temperature and in organic solvents on the 
enzyme, which exhibited much better activity for N-acetyl-3-(2-fluorenyl)-L-alanine 
methyl ester than the protease subtilisin did, as recently found in our lab. 
 
• Deacylation by acylases17 
Mori and Iwasawa reported the acylase-catalyzed deacetylation of N-acetyl-DL-amino 
acid derivatives, and used it to generate the enantiomers of threo-2-amino-3-
methylhexanoic acid. The reaction was carried out at pH 6.7 at 37 ºC for four days in the 
presence of CoCl2. The enzyme selectively deacylated the L-isomer and provided both 
enantiomers in high optical purity.11 
There are mainly two types of the acylases used for deacylation, one extracted from 
hog kidney, which has shown poor activity for substrates with bulky aromatic groups, 
and the other from aspergillus melleus with good activity for aromatic substrates.29 Sisido 
reported that an acylase (type unknown) failed to deacylate N-acetyl-3-(9-anthryl)-L-
alanine,20 while Matsubara found that acylase from aspergillus melleus succeeded in 
removing the acetyl group from N-acetyl-3-(2-anthraquinonyl)alanine.30 The reason for 
this difference wasn’t stated, but the type of acylases that made this difference is 
reasonably assumed. 
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There are several commercial acylases obtained from aspergills melleus with different 
enzymatic activities, distributed by Aldrich, Fluka and TCI. Amanoacylase from Aldrich 
has the highest activity at 30,000 µ/g, while another acylase from Fluka has 500 µ/g; no 
activity data was available for the TCI product. Compared with Fluka’s acylase, 
Aldrich’s amanoacylase is more efficient, which means that a lower catalyst/substrate 
ratio and shorter reaction time are required for the hydrolysis (Figure 1-11). 
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Figure 1-11   General pathway for deacylation by amanoacylase. 
 
1. 5. 3 Protection and deprotection of α-amino acid derivatives31 
Protection of amino or carboxyl groups are very important processes for peptide 
synthesis, in order to block functional groups that may participate in unwanted peptide 
bond formation. The nucleophilic reactivity of the α-amino group can be suppressed by 
pulling its electron density into a protective group or by shielding it sterically. Good 
protection and deprotection steps are those that can be done under mild, racemization-
free conditions. The protection should be easy to achieve and maintain until deprotection 
is required. The protective groups should be removable under mild conditions that have 
no adverse effect on other substitutents or the chiral center. Boc and Fmoc protection of 
amino groups are two common transformations used in solid-phase peptide synthesis. 
 
 16 
• Boc protection and deprotection 
The Boc group (t-BuOCO-) is applied extensively in peptide synthesis for amine 
protection, and is introduced with t-butoxycarbonyl azide or di-t-butyldicarbonate. A 
certain amount of side product formation, attributed to dipeptide or tripeptide formation, 
has been observed.32 To prevent these side reactions, the carboxyl group should be first 
converted to a trimethylsilyl ester with trimethylsilyl chloride. The trimethylsilyl ester is 
easily hydrolyzed back to the carboxylic acid after Boc protection. The Boc group is inert 
to basic hydrolysis and catalytic hydrogenation. It can be easily removed by TFA/CH2Cl2 
or HCl/dioxane. 
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Figure 1-12   General pathway for Boc protection and deprotection of the amino groups on α-amino acids. 
 
• Fmoc protection and deprotection 
The Fmoc group may be introduced by 9-fluorenylmethyloxycarbonyl chloride 
(Fmoc-Cl) or 9-fluorenylmethyloxycarbonyl-N-hydroxysuccinimide (Fmoc-OSu).31 For 
the amino acids with less hindered side chains, such as glycine or alanine, Fmoc-Cl can 
give small but detectable amounts of dipeptides and even tripeptides as side products. 
Fmoc-OSu is the reagent of choice for eliminating this oligomer formation. The Fmoc 
group has excellent acid stability. It can be quickly cleaved by 25% piperidine in DMF to 
afford the free amine and dibenzofulvene (Figure 1-13). 
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Figure 1-13   General pathways for Fmoc protection and deprotection of α-amino groups on the amino 
acids. 
 
1. 6 Solid-phase peptide synthesis33,34 
Peptide synthesis involves the formation of amide linkages (referred to as peptide 
bonds), which are formed by the reaction between the amino group of one amino acid and 
the carboxyl group of another amino acid (Figure 1-14). The formation of the peptide 
bond requires two fundamental operations: (1) activation of the carboxyl group, and (2) 
N-protection of the activated amino acid species, C-protection of the other one, and 
protection of any reactive functional groups on the side chain that may lead to side 
reaction during coupling. 
Peptide synthesis, whether in solution or on a resin, is a repetitive multi-step process, 
consisting of protection, activation, coupling and selective deprotection. The traditional 
solution-phase peptide synthesis requires equimolar amounts of reagents and complicated 
purification at each stage to remove the impurities. Such processes are time consuming 
and costly. Solid-phase peptide synthesis avoids these problems. 
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Figure 1-14   The formation of the peptide bond. R represents the alkyl or aromatic groups, and PG
   
 
indicates the protective group. 
 
The concept of solid-phase peptide synthesis (SPPS) was conceived by Merrifield in 
1959. Merrifield stated that, “One day, I had an idea about how the goal of a more 
efficient synthesis might be achieved. The plan was to assemble a peptide chain in a 
stepwise manner while it was attached at one end to a solid support. With the growing 
chain covalently anchored to an insoluble matrix at all stages of the synthesis, the peptide 
would also be completely insoluble and, furthermore, would be in a suitable physical 
form to permit rapid filtration and washing after completion of each of the synthetic 
reactions. The intermediate peptides in the synthesis would thus be purified by a very 
sample, rapid procedure rather than by the usual tedious crystallization methods. When a 
multistep process, such as the preparation of a long polypeptide or protein, is 
contemplated, the saving in time, effort and materials could be very large. The fact that 
all of the steps just described are heterogeneous reactions between a soluble reagent in 
the liquid phase and a growing peptide chain in the insoluble solid phase led to the 
introduction of the name – solid phase peptide synthesis.”34 With the developments in 
automation technology and parallel synthesis, the automatic solid-phase peptide synthesis 
was implemented, and further simplified peptide synthesis. 
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After the Boc-strategy peptide synthesis originally used by Merrifield, the Fmoc-
strategy was proposed by Sheppard in 1975. Although these methods adopt different 
protection groups for the amino groups, they use similar strategies: a resin support, 
excess coupling reagents, and building the peptide in a C→N terminal direction. The 
resin supports are swollen at the start in solvents and expand to many times their original 
size. Thus, the reactions don’t occur on the surface of a rigid particle, but within the 
solvated gel that the resin forms. Swelling permits easy access to the growing peptide 
chain. Reagents are used in excess, which drives the reactions to completion in the 
minimum time, resulting in faster synthesis of peptides and reducing side reactions or 
racemization. Proceeding in a C→N terminal direction allows use of racemization-
limiting amine protection for the activated species. 
 
1. 6. 1 Activation and coupling35,36 
Effective coupling requires chemical activation of the carboxyl group of an N-
protected α-amino acid. There are currently four major types of activating techniques, 
including use of acid halides, preformed symmetrical anhydrides, active esters and in situ 
activating reagents. Active esters and in situ reagents are the most commonly used 
coupling techniques for solid-phase synthesis. 
A pentafluorophenyl amino acid ester (Opfp) is a pre-activated amino acid, and can be 
stored and placed in the synthesizer during coupling.  By contrast, an OBt ester formed 
from DCC and HOBt, BOP, PyBOP, TBTU or HATU in situ (Figure 1-15) reacts so fast 
that it can’t be isolated.  
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Figure 1-15   Some common coupling reagents. 
 
In situ reagents are mixed with the amino acid derivative in the synthesizer, just prior 
to coupling. In situ reagents include DCC, BOP, PyBOP, HATU, TBTU, and PyAOP. 
Figure 1-16 describes the mechanism of peptide bond formation through DCC activation. 
HOBt and HOAt are used as the coupling additive here. The use of additives can inhibit 
side reactions and reduce racemization. 
More recently, HOAt has been found to be a more efficient additive that shortens 
coupling time and reduces the loss of chirality. The uronium and phosphonium salts are 
the most common coupling reagents, which in the presence of a tertiary base can 
smoothly convert protected amino acids to a variety of activated species. The most 
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common coupling reagents – BOP, PyBOP, HBTU and TBTU – generate HOBt esters. 
HATU is the uronium salt of HOAt, and has shown to be superior to other in situ 
reagents; it is used for the synthesis of difficult peptides (e. g., hydrophobic peptides, 
peptides containing hindered amino acids), and for assembly of peptide libraries. PyAOP, 
the phosphonium salt of HOAT, provides enhanced coupling activity and can be used as 
a direct substitute for BOP or PyBOP. It is beneficial in synthesis of cyclic peptides and 
for the addition of the first amino acid onto a hydroxyl resin. 
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Figure 1-16   The mechanism of activation and coupling through DCC. 
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1. 6. 2 Merrifield synthesis (Boc-strategy solid-phase peptide synthesis)37 
This methodology is characterized by use of tert-butyl based amino group protection 
(Figure 1-17). The first-loaded N-Boc amino acid is covalently attached to the resin, e.g., 
PAM resin. The use of PAM resin takes advantage of the fact that the presence of the 
electron-withdrawing 4-(aminoacyloxymethyl)phenylacetamidomethyl group increases 
the stability of the peptide ester in 50% TFA/CH2Cl2 during deprotection. 
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Figure 1-17   General pathway for BOC-strategy solid-phase peptide synthesis. 
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Boc-deprotection is followed by neutralization of the resulting ammonium salt with a 
hindered tertiary base, such as diisopropylethylamine (DIPEA) or triethylamine (TEA). 
The next N-Boc amino acid is activated and coupled with the resin-bound amino acid to 
yield an N-Boc dipeptide. The Boc-group is removed again, and the peptide chain 
continues to extend until completion of desired sequence. Before final cleavage of the 
target peptide from the resin, all side-chain protecting groups are removed. The anchoring 
ester bond between peptide and resin is broken by strong acids, usually HF or 
trifluoromethanesulphonic acid (TFMSA). Such procedures may require special 
apparatus (for HF) or scavenger reagents (for TFMSA) because the highly acidic 
conditions catalyze several possible rearrangements. The crude peptide is released and 
further purified by HPLC. 
 
1. 6. 3 Fmoc-strategy solid-phase peptide synthesis37 
The Fmoc-strategy arises from the adoption of the base labile Fmoc protecting group 
for α-amino group protection (Figure 1-18). Wang resin, one of the most common resins, 
consists of polystyrene beads onto which the acid-labile p-hydroxybenzyl alcohol linker 
is attached. As a result of the electron donating para oxygen atom stabilizing the resultant 
carbocation, cleavage of the peptide from the resin occurs under rather mild acid 
conditions, typically TFA in the presence of scavengers. 
 
1. 6. 4 Comparison of Boc- and Fmoc-strategies 
In the Boc-strategy, repetitive TFA acidolysis to remove Boc protecting groups may 
lead to acid-catalyzed side reactions. Cleavage of the peptide from the resin requires the 
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use of strong acids, which may lead to more side products, reduce the purity of the 
desired peptide and complicate the purification. The advantage of the Fmoc-strategy is 
that the growing peptide is subjected to mild bases such as piperidine during 
deprotection; TFA is required only for the final cleavage. In addition, the progress of 
each coupling and deprotection step can be monitored by measurement of the absorbance 
of the cleaved Fmoc group at 300-320 nm. 
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Figure 1-18   General pathway for Fmoc-strategy solid-phase peptide synthesis. 
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1. 6. 5 Cyclic peptides and peptide cyclization38 
There are two types of cyclic peptides: homodetic and heterodetic. In homodetic cyclic 
peptides, the amino acid residues are connected only by the usual amide linkage between 
amino and carboxylic acid groups, whereas the presence of other linkages such as 
lactone, ether, thioether, or the disulfide bridge make a peptide heterodetic. 
 
• Cyclization in solution 
In general, cyclic peptides are synthetically challenging.39 Cyclic peptides are more 
difficult to synthesize than linear oligomers, since the desirable intramolecular 
cyclization may be replaced by the competitive linear peptide chain propagation or 
intermolecular cyclization, unless a particularly stable ring is formed or specific 
molecular auxiliaries are employed. 
The protected peptide must be cleaved from the solid support before cyclization in 
solution is attempted. The cyclization conditions are similar to those used in coupling of 
the linear peptide. The only difference is that very dilute concentrations of the linear 
peptide (usually, 0.5-1 mM) and coupling reagents (0.5-3 mM) are used in order to 
minimize the formation of the cyclodimer and oligomers. Linear dimerization, 
cyclodimerization and cyclooligomerizations may still occur even under high dilution as 
side reactions. Generally, it is necessary to isolate the desired peptide from excess 
reagents and side products by HPLC to obtain the product with good purity.5,40 
 
• Cyclization on a resin8,41 
 26 
On-resin cyclization requires that two reactive groups, an amino and a carboxylic acid 
group, not be directly attached to the resin and that another functional group on the side 
chain is used to make the covalent link to the resin. This set of characteristics makes it 
possible to cyclize the linear peptide on the solid resin, where pseudodilution is achieved 
because the solid support provides a large distance between the different peptide 
molecules. Thus intramolecular is preferred over intermolecular cyclization. 
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Chapter 2   Synthetic Targets and Procedures 
 
The chromophore-modified chiral amino acids that we designed and synthesized are 
N-Boc-3-(9-anthryl)-L-alanine (Boc-An-Ala, 7) and N-Fmoc-3-(N-ethyl-3-carbazolyl)-L-
alanine (Fmoc-Car-Ala, 25). Fmoc-Car-Ala was to be incorporated into an 8-mer 
bichromophoric linear peptide with benzophone as the second chromophore (H-Aib-Car-
Aib-Phe-Aib-Bpa-Aib-Phe-OH, 28). This linear peptide was then cyclized to the 
corresponding cyclic peptide, cyclo(Aib-Car-Aib-Phe-Aib-Bpa-Aib-Phe, 29) (Figure 2-
1). 
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Figure 2-1   Our intermediates and target products. 
 
We decided to resolve the D,L-amino acids by enzymatic hydrolysis to secure a high 
enantiomeric excess. The Sorensen method, Erlenmeyer’s azlactone method and the 
Wittig-Horner reaction were each tried in our attempts to build the amino acid skeletons. 
For peptide synthesis, suitable protection of amino or carboxyl group is necessary. We 
attempted two most common amino group transformations, Boc or Fmoc protection, 
depending on the strategy for peptide synthesis that we chose, and methyl esterification 
for C-protection. 
Solid-phase peptide synthesis was carried out. Two model peptides were initially 
synthesized, one by Boc-strategy, and the other by Fmoc-strategy, to seek the optimal 
conditions before we started with the target peptide (Figure 2-2). 
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Figure 2-2   Two model linear peptides. 
 
2. 1 Synthesis of N-Boc-9-anthryl-L-alanine 
Sisido had reported the synthesis of N-Ac-3-(9-anthryl)-DL-alanine by the Sorensen 
method (Figure 2-3).20,42,43 First, sodium ethoxide deprotonated the active hydrogen from 
diethyl acetamidomalonate. The carbanion formed attacked 9-chloromethylanthracene to 
give an alkylated diester, which was hydrolyzed and decarboxylated. 
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Erlenmeyer’s azlactone route is not applicable for this compound, because reduction 
of the exocyclic double bond in the intermediate also leads to reduction at the anthracene 
9, 10-positions (Figure 2-4).22 
We chose Sisido’s pathway for synthesis of N-Ac-3-(9-anthryl)-DL-alanine (Scheme 
3-1), except for small adjustments made following David Ferguson’s p rocedure for 
synthesis of 3-(2-fluorenyl)-DL-alanine.44 NaH was used as the base instead of sodium 
due to ease of handling of the former. 
 
Cl
Na, EtOH
NHAc
HO
OH
NHAc
HO
OH
EtOH
H3O+
H3O+
NHAc
HO
O-L-ephedrine-H+
AcHN
OEt
OO
EtO
1. NaOH (4eq), EtOH
NH3+Cl-
HO
OH
NHAc
HO
O-L-ephedrine-H+
AcHN
OH
O
H
+
6M HCl, AcOH
diethyl acetamidomalonate
reflux
Ac-DL-An-Ala
L-ephedrine
(LL) (DL)
(DL)
(LL)
2. HCl
Ac-DL-An-Ala
 
Figure 2-3   The pathway for synthesis of Ac-L-An-Ala and D-An-Ala via Sorensen method by Sisido.20 
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According to Sisido’s report, acylase failed to remove the acetyl group from N -Ac-3-
(9-anthryl)-DL-alanine.20 Nestor also reported that enzymatic hydrolysis didn’t work for 
N-Ac-3-(9-anthryl)-DL-alanine methyl ester and the derivative of 3-(9,10-dihydro-9-
anthryl)-DL-alanine.22 The major reason is the bulkiness and hydrophobicity of the 9-
anthryl group. Sisido used a chiral auxiliary, L-ephedrin, that can form salts with N-Ac-
DL-amino acids. The diastereoisomeric products were separated by stepwise 
precipitation, and then decomposed into the two enantiomers, whose methyl ester 
derivatives were identified by NMR with the aid of a chiral shift reagent.20,42 The same 
experiment was repeated in our lab, but good resolution couldn’t be achieved  because the 
compound didn’t dissolve well in hot EtOH as reported, or in other solvents, such as 
acetone, CH2Cl2, CHCl3, EtOAc, and MeCN. 
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Figure 2-4   The pathway for synthesis of N-Boc-3-(9,10-dihydro-9-anthryl)-DL-alanine via the 
Erlenmeyer azlactone method by Nestor.22 
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Before enzyme-catalyzed ester hydrolysis, methyl esterification is an indispensable 
step. BF3•Et2O was chosen as the catalyst for this transformation instead of conc. HCl, to 
avoid the introduction of any water that might affect the yield. In addition, two other 
methods for methyl esterification were attempted in order to seek higher yields (Figure 2-
5). Thionyl chloride18 and trimethylsilyldiazomethane45 were used as the reactive 
reagents; the reaction involving the latter proceeds in a shorter time at room temperature. 
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Figure 2-5   Different methods for methyl esterification of N-Ac-3-(9-anthryl)-DL-alanine. 
 
Subtilisin ChiroCLEC-BL and acylase from aspergillus melleus are two powerful 
enzymes. The former efficiently removed the methyl group from N-Ac-3-(2-fluorenyl)-
DL-alanine methyl ester (Figure 2-6(a)),44 while the latter removed the acetyl group from 
N-acetyl-3-(2-anthraquinonyl)-DL-alanine (Figure 2-6(b)).30 In our substrate, C-9 of the 
anthryl group is attached to C-3 of the alanine, which may be more sterically hindered 
than having C-2 of the fluorenyl group attached to C-3. Moreover, the solubility of the 9-
anthryl derivative is much poorer than that of the 2-fluorenyl one in acetone or other 
organic solvents. As for the two anthryl derivatives, one is substituted at C-9, the other at 
C-2. The steric hindrance is probably greater for the first case. Since the stereochemical 
interaction between enzyme and substrate will determine the hydrolytic efficiency, higher 
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steric hindrance and poor solubility of the substrates may make the resolution slower and 
selectivity poorer. 
We adopted both these enzymes to sequentially remove the two protective groups 
from our substrates. The dual enzymatic resolutions simplify the purification because the 
D-isomer has been removed before deacylation, securing high enantiometric excess and 
avoiding the acid-catalyzed side reactions during normal deacylation that take place in 
conc. HCl/AcOH under lengthy reflux. 
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Figure 2-6   (a) Ester hydrolysis catalyzed by ChiroCLEC-BL; 
                     (b) deacylation catalyzed by aspergillus acylase. 
 
The normal conditions for Boc protection of the free amino group, like that in L-
proline, is shown in Figure 2-7. When these conditions are applied to sterically hindered 
amino acids, only 40-60% yields have been obtained.18 For Boc protection of 3-(9-
anthryl)-L-alanine, DMF was chosen as the solvent to enhance solubility of the starting 
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material. 
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Figure 2-7   Boc-protection of L-proline. 
 
An alternative synthetic scheme was designed to directly make the N-Boc amino acid 
derivatives,46,47,48 where N-Boc-amidomalonate replaced its acetyl derivative to give an 
N-Boc diester (Figure 2-8a). ChiroCLEC-BL can be used to remove the methyl ester  
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Figure 2-8   (a) Modified Sorensen method to directly generate an N-Boc diester; 
                     (b) ester hydrolysis of N-Boc-3-(2-naphthyl)-L-alanine methyl ester catalyzed by 
ChiroCLEC-BL. 
 
from N-Boc derivatives, according to Wang’s report that ChiroCLEC -BL 
hydrolyzed N-Boc-3-(2-naphthyl)-L-alanine methyl ester (Figure 2-8b).28 We 
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attempted to synthesize N-Boc-3-(9-anthryl)-DL-alanine methyl ester first, 
followed by ester hydrolysis via the catalysis of ChiroCLEC-BL (Scheme 3-2). 
 
2. 2 Synthesis of 3-(N-ethyl-3-carbazolyl)-L-alanine and its derivatives 
In my initial attempt to obtain 3-(N-ethyl-3-carbazolyl)-DL-alanine via the Sorensen 
method, the desired intermediate, N-ethyl-3-chloromethylcarbazole, could not be 
obtained from SOCl2 and the corresponding alcohol (Figure 2-9). Instead, an unexpected 
blue side product was observed. 
 
N
CHO
Et
N
Et
CH2OH
pyridine, 0° C N
Et
CH2ClNaBH4, MeOH
SOCl2, THF
rt
 
Figure 2-9   Unsuccessful pathway to N-ethyl-3-chloromethylcarbazole. 
 
Taku reported the preparation of 3-(N-ethyl-3-carbazolyl)-DL-alanine by the azlactone 
route (Figure 2-10).23 We repeated the synthesis (Scheme 3-3), but a major problem was 
met during removal of the benzoyl group by refluxing with conc. HCl/AcOH. It will be 
discussed in detail later. 
An alternative approach to removing the benzoyl group was attempted, where the 
oxazolone is treated with red P, Ac2O and aq. HI. The mixture was heated to 140 °C 
(Figure 2-11). The reactions, involving reduction, ring-opening, and deacylation took 
place simultaneously in one pot. 
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Figure 2-10   Erlenmeyer azlactone route to produce 3-(N-ethyl-3-carbazolyl)-DL-alanine by Taku.23 
 
The Wittig-Horner reaction provides mild conditions to make N-protected 
dehydroamino acid methyl esters,49,50 and was our next choice for synthesis of 3-(N-
ethyl-3-carbazolyl)-DL-alanine (Scheme 3-4). 
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Figure 2-11   Reduction, hydrolysis and debenzoylation of 4-(3-(N-ethylcarbazolylidene)-2-phenyloxazol-
5-one. 
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The Wittig-Horner reaction starts with an aromatic aldehyde and an N-protected 
phosphonoglycinate. N-Cbz-phosphonoglycinate is the only commercial derivative, 
which can be easily converted to Boc and Ac derivatives (Figure 2-12).51 The Cbz group 
is removed first by catalytic hydrogenation, followed by Boc-protection. A one-step 
conversion has also been applied to transform the Cbz to the acetyl derivative.  In the 
Wittig-Horner reaction of aldehydes with phosphonates, tetramethylguanidine is a 
common base used to create the carbanion, which attacks the carbonyl group and couples 
the two components together (Figure 2-13).52 
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Figure 2-12   The conversion of an N-Cbz-phosphonoglycinate to its corresponding Boc or Ac 
derivatives.51 
 
The hydrogenated product carrying two protecting groups, the N-protective group (N-
Boc or N-Ac) and the methyl ester, would be ready for selective hydrolysis by the two 
kinds of the enzymes to provide the desired L-isomer. 
For Fmoc protection, Fmoc-OSu was chosen as the Fmoc reagent to avoid side 
products, which may form when Fmoc-Cl is used.  Many factors, such as solubility of the 
substrate, possible racemization, and deprotection under basic conditions had to be 
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considered in choosing the best conditions for protecting our substrate. Protection and 
deprotection seemed to be competitive reactions under basic conditions. In order to avoid 
deprotection of the product, fast reaction is necessary. Strong base may cause both 
deprotection and racemization of the chiral amino acids, so the pH is generally kept 
between 9 and 11 (Figure 1-13). 
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Figure 2-13   Synthesis of methyl 2-Cbz-5,5-(2,2-dimethylpropane-1,3-diyldioxy)pent-2-enoate by the 
Wittig-Horner reaction with a phosphonoglycinate.52 
 
2. 3 Syntheses of polypeptides35,36 
The major task of this research was to incorporate the chromophore-modified amino 
acids into the peptide skeletons. Before building the target linear peptide 28 and cyclic 
peptide 29, two model peptides were synthesized by Boc-strategy SPPS and Fmoc-
strategy SPPS, respectively, in order to compare the feasibility of two synthetic methods. 
 
• 4-Mer model peptide obtained by Boc-strategy SPPS (26) 
For the 4-mer model peptide synthesis via the Boc-strategy, there are a number of 
common conditions that apply to all steps of the same procedure. As we have discussed 
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above, PAM resin was chosen for Boc-strategy syntheses. 
 
Swelling: N2 bubbling in 10 mL of CH2Cl2 with 0.2-1 g of resin. 
Deprotection: use of 50% TFA/CH2Cl2 for 30 min, twice. The end point is signaled by a 
positive ninhydrin test. 
Washing after deprotection: washing with CH2Cl2, neutralizing with 20% DIPEA in 
CH2Cl2, and washing with DMF, MeOH, and CH2Cl2. 
Activation and coupling: adding 5 eq N-Boc amino acid, 5 eq PyBOP, 5 eq HOBT, and 
10 eq DIPEA dissolved in DMF. The coupling reagents are poured onto the resin with N2 
bubbling for the required time period. A negative dye test signals the completion of 
coupling. If the dye test is positive, one repetition of the coupling step may be required. 
Washing after coupling: washing with DMF, MeOH, EtOH and CH2Cl2. 
Final washing before cleavage: washing with DMF, CH2Cl2, MeOH, and EtOAc and 
drying the resin in vacuum. 
Cleavage: mixing the dry resin with thiolanisole, ethanedithiol, TFA and TFMSA and 
stirring for one hour. 
 
• 8-Mer model peptide by Fmoc-strategy SPPS (27) 
For the 8-mer model peptide synthesis via the Fmoc-strategy, some additional details 
need be mentioned. DMF was used instead of CH2Cl2, and no neutralization required. 
 
Resin choice: Wang resin was chosen. 
Swelling: N2 bubbling in 10 mL of CH2Cl2 with 0.2-1 g of resin. 
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Deprotection: use of 25% piperidine in DMF for 30 min, twice. The Kaiser test is used to 
indicate the presence of primary amines, the chloranil test for secondary amines, and the 
TNBS test for highly hindered primary amines. 
Washing: washing with DMF, CH2Cl2, and DMF. No neutralization is required. 
Activation and coupling: same as above, but for difficult sequences, extension of the 
reaction time, or more powerful coupling reagents are used (HOAt and PyBOP or HOAt 
and HATU). 
Cleavage: use of TFA/H2O (95:5) for two hours. Scavenging reagents may be required, 
depending on the amino acids present. 
 
• Linear target peptide (28) 
Based on the results of the syntheses of two model peptides, an improved synthetic 
strategy was designed to achieve the target peptide. 
 
• Cyclic target peptide (29) 
Cyclization was carried out according to Ghadiri’s procedure for an 8 -mer cyclic 
peptide, cyclo(-L-Phe-D-N-MeAla-)4.5  The cyclization was done in DMF (1 mM 
substrate) at 0 °C in the presence of 3 eq HATU, 3 eq HOAt, and 10 eq DIPEA to give a 
70% yield of the cyclic peptide after further purification by RP-HPLC. HOAT and 
HATU were used in place of HOBT and PyBOP, which speeded up the cyclization. 
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Chapter 3   Results and Discussion 
 
This chapter describes the syntheses and resolutions of two unnatural amino acids, and 
their use in several linear and cyclic peptides. 
 
3. 1 Syntheses of Boc-3-(9-anthryl)-L-alanine 
The Sorensen method was used to synthesize N-Ac-3-(9-anthryl)-L-alanine (5, 
Scheme 3-1). Many strategies were considered in order to increase the yield of alkylation 
of diethyl acetamidomalonate by 9-chloromethyl-anthracene. According to the SN2 
mechanism, extended reaction time, high concentrations of the starting materials, and 
elevated temperature increase the yield to some degree. The leaving activity of chloride is 
lower than bromide. Therefore, addition of a small amount of LiBr as catalyst 
transformed the chloride to a bromide intermediate, and sped up the conversion. The 
yield was increased to 70% from 39% as a result. 
Enzymatic hydrolysis is the key step in this synthesis. Dual enzymatic resolutions 
were designed to remove the methyl group of 4 by ChiroCLEC-BL and the acetyl group 
of 5 by amanoacylase. 
ChiroCLEC-BL failed to remove the methyl group from N-Ac-9-anthryl-L-alanine 
methyl ester (4) under routine conditions in acetone-phosphate buffer at 37 °C for four 
days with shaking, due to the bulkiness of the 9-anthryl group and poor solubility of this  
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Scheme 3-1 
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substrate. The temperatures and solvents were varied to seek the optimal hydrolytic 
conditions (Table 3-1). Finally, we achieved a good resolution in DMF at 60 °C for three 
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days. The conversion was 40% (yield 80%), which was calculated from NMR-7. There 
were two peaks assigned to the CH3 groups of the acetyl groups, one belonging to 4 
located at δ 1.69, the other belonging to 5 at δ 1.67. The ratio of the integrals was 6:4 
(4/5, Figure 3-1). 
 
Table 3-1 Experiments aimed at optimizing the enzymatic resolution of N-Ac-3-(9-anthryl)-DL-alanine 
methyl ester (4). 
 
There are peaks due to unknown impurities appearing on NMR-9 (N-Ac-3-(9-anthryl)-
L- alanine, 5) and on NMR-6 (N-Ac-3-(9-anthryl)-DL-alanine methyl ester, 4) after 
resolution. It was assumed that a small part of ChiroCLEC-BL might have dissolved in 
DMF after three days of enzymatic hydrolysis at 60 °C, or that it wasn’t completely 
removed by centrifugation. The impurity wasn’t observed on TLC, but it did contaminate 
the NMR spectrum. 
Experiment 
No. 
Enzyme 
Types 
Solvent Temperature 
(°C) 
Time 
(days) 
Yield by TLC 
(%) 
1 Protease Acetone 37 
2 
4 
~ 10% 
No obvious change on TLC 
 
2 ChiroCLEC-BL Acetone 37 
2 
4 
~ 10% 
No obvious change on TLC 
3 ChiroCLEC-BL DMF 60 
2 
3 
5 
~ 60%  
~ 80%  
No obvious change on TLC 
4 ChiroCLEC-BL 
Acetone 
DMF 60 
2 
4 
5 
~ 20% 
~ 60% 
No obvious change on TLC 
5 ChiroCLEC-BL 
THF 
DMF 
37 
60 
60 
1 
2 
5 
6 
8 
 
No obvious reaction 
~10% 
~ 60%  
~ 70% 
~ 70% 
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The enantiomeric excess is commonly determined from NMR spectra with the aid of a 
chiral shift reagent. Tris[3-(trifluoromethylhydroxymethylene)-d-camphorato]europium 
(III) was used as the chiral reagent to resolve the signals from N-Ac-3-(9-anthryl)-DL-
alanine methyl ester (4). A quartet assigned to CH showed up at δ 4.99-5.04 without the 
chiral reagent (NMR-6), while two broadened and low-intensity peaks overlapped each 
other at δ 5.89-6.12 after addition of the chiral reagent (NMR-8).  There is no clear 
border between two peaks and so it is impossible to integrate the individual peaks to 
calculate the relative amount of each (Figure 3-2). 
 
 
Figure 3-1   1H NMR CH3 peaks of the acetyl groups assigned to compounds 4 (left) and 5 (right), 
respectively. 
 
Next, deacylation was done in two ways:  by heating 4 to reflux in strong acid and by 
using a powerful enzyme, amanoacylase. Hydrolysis under the first conditions did not 
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give a clean product  an unknown side product was observed by TLC, and black spots 
(which may come from decomposition of the impurity) were seen with the naked eye. 
Deacylation by amanoacylase was clean and efficient; 89% yield was observed by TLC 
after two days. The mild reaction conditions (pH 7.5 buffer, 37 °C) avoided racemization 
or acid-catalyzed side-reactions. 
 
 
                                                              (a)                   (b) 
Figure 3-2   The CH peak in the 1H NMR spectrum of N-Ac-3-(9-anthryl)-DL-alanine methyl ester (a) 
without the chiral shift reagent; (b) with the chiral shift reagent. (sample/chiral shift reagent 5:3 mole ratio). 
 
The overall yield for the process shown in Scheme 3-1 was 9.5%. 
Scheme 3-2 represents an alternative route for synthesizing N-Boc-3-(9-anthryl)-L-
alanine (7). When one carboxylic group was removed from the dicarboxylic acid by 
heating to reflux in a weakly acidic media overnight, the Boc group was also removed. 
The free amino group had to be Boc-protected again after methyl esterification. 
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Scheme 3-2 
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In order to protect the Boc group during decarboxylation, the pH was adjusted to 7 and 
the solution was heated to reflux in dioxane for five hours. The Boc group survived this 
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time. The following methyl esterification with trimethylsilyl-diazomethane gave a 70 % 
yield. 
There is no big difference in yield for three methyl esterfication conditions that we 
have adopted. The advantage of using trimethylsilyldiazomethane was that the reaction 
proceeded rapidly at rt under acid-free conditions.The Boc protection step gave higher 
yields with the C-protected amino acid derivative (75%) than with the free amino acid 
(45%). 
The enzyme-catalyzed hydrolysis of the Boc-protected esters became more difficult 
due to greater steric hindrance and poorer solubility. Different solvents (DMF, THF, 
dioxane), temperatures (37-60 °C), enzyme concentrations and time periods (up to five 
days) were tried and failed to bring about good resolution. After comparing the sizes of 
the spots assigned to N-Boc-3-(9-anthryl)-L-alanine (7) and N-Boc-3-(9-anthryl)-DL-
alanine methyl ester (10) on TLC, it was estimated that about 20% of yield was achieved 
under one set of conditions (DMF, 60 °C, three days), but after further work-up, only 8% 
of the desired product was obtained. It is assumed that either the size of the spots on TLC 
didn’t reflect the content of each component for this system, or that the applied work -up 
conditions were faulty. 
This N-Boc-amino acid methyl ester didn’t seem to be a good substrate for 
ChiroCLEC-BL. It may be due to its hydrophobicity or to the bulky Boc group that may 
affect complexation between the enzyme and its substrate. Another kind of enzyme, 
papain, was reported to be used for hydrolysis of the N-Boc-amino acid methyl ester, but 
the enantiomeric excess (80%) wasn’t really satisfactory. 24 The same problem was met in 
enzymatic hydrolysis of N-Boc-3-(N’ -ethyl-3-carbazolyl)-DL-alanine methyl ester (21a) 
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later. The enzymatic hydrolysis of 3-(N-ethyl-3-carbazolyl)-DL-alanine methyl ester also 
failed, and multiple side-products were displayed on TLC. This failure may be 
attributable to the weak bonding between this enzyme and its substrate. 
 
3. 2 Attempted syntheses of 3-(N-ethyl-3-carbazolyl)-DL-alanine 
The first attempt at synthesis of 3-(N-ethyl-3-carbazolyl)-DL-alanine by the Sorensen 
method failed in the second step, where N-ethyl-3-hydroxymethylcarbazole (13) was 
expected to be converted to the chloride by SOCl2. The solution turned blue when it was 
warmed to rt after addition of SOCl2. Figure 3-3 suggests the potential side reactions 
under these conditions. 
 
N
Et
OH
N
Et
Cl
N
X
N
Et Et
X
SOCl2, THF
X may Cl, OH, OSOCl 
or additional rings
Is it blue?
pyridine, 0 °C
pyridine, 0 °C
SOCl2, THF
N
Et
CHO NaBH4, MeOH
rt
70% 13
13
 
Figure 3-3   Potential side reactions in the transformation from a carbazolylmethanol to the chloride 
derivative. 
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The azlactone route was used to synthesize 3-(N-ethyl-3-carbazolyl)alanine (Scheme 
3-3). The oxazolone was prepared by condensation between carbazolecarboxaldehyde 
and benzoylglycine. 
The ring was opened in basic solution and the double bond was reduced by catalytic 
hydrogenation. The following step, heating in 6M HCl/AcOH, was required to remove 
the benzoyl group. The deep blue byproduct was observed after four hours of reflux. The 
blue disappeared when the solution was made basic, and the blue came back when the 
acid was added again. It functioned as a reversible acid-base indicator such as those with 
the blue product showed similarity to that of the starting material, although there was a 
slight change in the integration of the aromatic protons. In order to speed up the large 
conjugated structures (e.g., as triphenylmethane dyes). The 1H NMR spectrum of 
deacylation, hippuric acid was replaced with N-acetyl-glycine and 4-nitrobenzoylglycine, 
which were condensed with the aldehyde. During deacylation, the blue byproducts were 
again present. HBr and HI were used in place of HCl to speed up the reaction, and the 
reaction temperature was reduced to 80 °C, but the blue product appeared again after five 
hours of refluxing. 
Two small reactions were set up, where carbazole and 9-ethyl-3-carbazole- 
carboxaldehyde, respectively, were refluxed in HCl/AcOH solution. After a couple of 
hours, the deep blue color was observed in both cases, which may be the best evidence 
that the reaction involved the carbazole ring. But its potential structure was unknown 
until a compound called carbazole blue was located in a 1920 journal article.52 Carbazole 
blue was first obtained by Suida from the fusing of carbazole with oxalic acid in 1879. 
Copisarow made carbazole violet when 9-ethylcarbazole was fused with oxalic  
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acid. Copisarow thought that carbazole condenses in this case, not with oxalic acid itself, 
but with its decomposition product, formic acid. Figure 3-4 describes the potential 
reactions and the deduced structure of the products. 
Scheme 3-3 
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Figure 3-4   Formation and assumed structures of carbazole blue and carbazole violet.56 
 
The proposed reaction in our case is described in Figure 3-5. The two carbazole rings 
were assumed to condense with benzoic acid instead of formic acid. 
In order to securely remove the benzoyl group, an alternative method was adopted, 
where the oxazolone was treated with red phosphorus, Ac2O and aqueous HI. A series of 
reactions, involving reduction, ring-opening, and deacylation took place during seven 
hours of refluxing. The blue product wasn’t observed this time. A positive ninhydrin test 
indicated that the benzoyl group had been removed, but there were several TLC spots 
showing positive ninhydrin tests. Their similar polarities made them hard to separate. 
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Figure 3-5   The assumed side reaction during debenzoylation of compound 16a. 
 
3. 3 Syntheses of N-Fmoc-3-(N’-ethyl-3-carbazolyl)-L-alanine and its 
derivatives via Wittig-Horner reactions followed by two-step 
enantiomeric resolutions 
The liability of 3-(N-ethylcarbazoyl)-DL-alanine to acid blocked its synthesis by the 
Sorensen or azlactone routes. Thus, the Wittig-Horner route was a good alternative to 
create the amino acid backbone. All reactions took place under mild conditions at rt. The 
yield for each step was fairly good (Scheme 3-4). 
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Scheme 3-4 
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Thus theWittig-Horner reaction was adopted to create this amino acid. CBZ-protected 
phosphonoglycinate was converted to its N-Boc derivative (18) by hydrogenolysis and N-
Boc protection, and to N-Ac derivative (19) by one-pot reaction involving CBZ-
deprotection and acylation. The following Wittig-Horner reaction proceeded under mild 
conditions, where TMG was used as base. The reaction was stirred at -70 °C for one hour, 
and was continued at rt for 18 hours. On the 1H NMR spectrum of 20b (Figure 3-6(a)), 
there were two singlet peaks located at δ 2.15 and 1.85, which were assigned to the acetyl 
groups of N-acetyl-3-(N’ -ethyl-3-carbazolyl)-DL-acrylic acid methyl ester (20b), 
belonging to E and Z isomers, respectively. After hydrogenation, these two CH3 peaks 
merged into one on the 1H NMR spectrum of 21b (Figure 3-6(b)). 
ChiroCLEC-BL was chosen to selectively hydrolyze the methyl ester, but it didn’t 
work well for the N-Boc-amino acid methyl ester (21a). Changing solvents (DMF, THF, 
and dioxane), temperatures (37-60 °C), amount of enzyme and time periods (up to five 
days) failed to produce good resolutions. After comparing the sizes of spots assigned to 
N-Boc-3-(N’ -ethyl-3-carbazolyl)-L-alanine (22) and N-Boc-3-(N’ -ethyl-3-carbazolyl)-
DL-alanine methyl ester (21a) on TLC, it was estimated that about 40% of yield was 
achieved under favorable conditions (DMF, 60 °C, 72 hr). Eventually, only 16% of the 
desired product was isolated. 
N-Ac-3-(N’ -ethyl-3-carbazolyl)-DL-alanine methyl ester (21b) was synthesized by the 
same pathway, as shown in Scheme 3-4. Its L-isomer (23) was found to be a good 
substrate for ChiroCLEC-BL. The hydrolysis was complete in acetone-phosphate buffer 
at 37 °C after 24 hr (yield 100%). This hydrolytic product is also a good substrate for 
amanoacylase. The deacylation was complete in pH 7.5 buffer at 37 °C after 24 hr (yield 
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100%). Dry reverse-phase flash column chromatography was used to purify the highly 
polar 3-(N-ethyl-3-carbazolyl)-L-alanine (24). The difference between this technique and 
the conventional wet reverse-phase flash column chromatography is that the former relies 
on suction rather than a slight positive pressure to force the organic mobile phase through  
 
(a)  
 
(b)          
 
Figure 3-6   1H NMR spectra for 20b (a) and 21b (b). 
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a silica-gel column, which enables rapid and efficient mobile phase flow and gives the 
possibility of separating polar compounds on a preparative scale.18 It can also avoid the 
tailings and loss of the free amino acid that occurs when a normal-phase silica gel column 
is used. 
 
The chiral reverse-phase TLC was used to attempt to resolve the D,L mixture of the 
free amino acids and estimate the enantiomeric excess. Separations of DL-methionine 
and DL-proline were observed on the chiral TLC plates. However, only one spot with a 
long tail was observed for DL-alanine, and only one spot was seen for DL-aspartic acid 
and DL-threonine. There was no separation observed for the 3-(N-ethyl-3-carbazolyl)-L-
alanine (24), but that fact can’t guarantee that only one isomer exists in the product.  
Fmoc protection was carried out in 5% Na2CO3/dioxane at rt for four hours (yield 
40%). After purification by normal-phase column chromatography, a light yellow solid 
was obtained. Two close spots appeared on TLC plate. Final recrystallization removed 
the impurity and the product was obtained purely as a white solid. 
The N-acetyl-3-(N’ -ethyl-3-carbazolyl)alanine derivatives have low-melting points 
and good solubility in most organic solvents. They do not form good crystals, but instead 
a foam-like solid after drying under the vacuum. The solvent may be trapped inside the 
foam, and difficult to completely remove. That may be the cause of the impurity peaks 
showing up on the NMR spectra. 
The overall yield for synthesizing 25 by Scheme 3-4 was 23%. 
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3. 4 Solid-phase peptide synthesis 
In comparing the Boc-strategy and Fmoc-strategy solid-phase peptide syntheses, it is 
evident that better purity and yield would be achieved with the Fmoc-strategy SPPS. The 
latter is much easier to operate, especially for peptides with sensitive groups. In the Boc-
strategy, strong acids, e.g., TFMSA, are applied to cleave the desired peptides from the 
resin. This process is very susceptible to salt and scavenger association. The precipitated 
peptides have to be neutralized and the salts removed either by ion exchange or by 
Sephadex column chromatography before further purification by HPLC.36 
The above analysis was confirmed by our preliminary attempt at syntheses of two 
model peptides, 4-mer (26) and 8-mer (27) linear peptides. Eventually, the Fmoc-strategy 
was adopted to make the desired 8-mer linear peptide, H-Aib-Car-Aib-Phe-Aib-Bpa-Aib-
Phe-OH (28). Subsequent cyclization in solution afforded the target cyclic peptide, 
cyclo(Aib-Car-Aib-Phe-Aib-Bpa-Aib-Phe) (29). 
The first model peptide, H-Car-D-Ala-Bpa-D-Ala-OH (26), was synthesized by the 
Boc-strategy. The reaction was carried out on Pam resin. After the peptide was cleaved 
from the resin, purification became a big problem. First, this peptide didn’t precipitate in 
cold Et2O, even though TFA had been almost completely removed. The residue was 
heated to 80 º C to remove the solvents as much as possible. A light yellow precipitate 
was obtained and analyzed by ES-MS. Its ES-MS spectrum was very complicated and 
many impurity peaks showed up (MS-3). The molecular ion peak couldn’t be located. A 
major peak at m/z 791.4, which was assigned to the TFA salt of the desired peptide 
(calcd. 790.8), was observed. 
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An 8-mer peptide, H-D-Ala-Npa-D-MeAla-Ala-D-Ala-Bpa-D-Ala-Ala-OH (27), was 
synthesized by the Fmoc strategy. The reaction was carried out on the Wang-resin. 
Before the final deprotection, 70 mg of resin-bound peptide, H-D-FmocAla-Npa-D-
MeAla-Ala-D-Ala-Bpa-D-Ala-Ala-OH, was set aside. The Fmoc group was removed 
from the remaining 200 mg of the resin by 25% piperidine. The two peptide-bound resin 
samples were cleaved under mild conditions (TFA/H2O 95:5). They both gave 
precipitates in cold Et2O. The ES-MS spectrum of the Fmoc-deprotected peptide seemed 
pretty clean (MS-4). The molecular ion peak [M + 1]+ was identified at m/z 907.2 (calcd. 
907.0).  For the Fmoc protected peptide, no molecular ion peak was observed (calcd m/z 
1115.1 [M + 1]+, (MS-7)). Its absence may be due to poor solubility of the N-Fmoc 
peptide in TFA, and so the cleaved peptide may stay with the resin during workup. 
Syntheses of the 8-mer target peptide (28) were carried out twice by the Fmoc-
strategy. The first time, after Fmoc-Aib was attached to the resin and then its Fmoc group 
removed, the ninhydrin test gave a negative result. In the following attachment of Fmoc-
Bpa to the resin, another negative ninhydrin test was observed after deprotection. It 
wasn’t clear which step had failed to attach an amino acid onto the resin -bound peptide. 
After the total synthesis had been completed, the ES-MS gave the major peak at m/z 
917.6 (MS-8), which belonged to H-Aib-Car-Aib-Phe-Aib-Aib-Phe-OH, Therefore, 
Fmoc-Bpa failed to attach to the resin-bound peptide. The second synthesis was 
successful. TNBS and chloranil tests were adopted to monitor the deprotection after the 
Fmoc-Aib attachment. Only one peak appeared on MS-5, which corresponded to the 
molecular ion peak, [M + 1]+, found at m/z 1168.8 (calcd. 1168.6). 
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Two cyclization attempts were made for synthesis of cyclo(Aib-Car-Aib-Phe-Aib-
Bpa-Aib-Phe, 29). The first gave a 40% yield. There were three major peaks in its MS 
spectrum (MS-6), at m/z 1150.8 (belonging to [M + 1]+), at m/z 1172.8 (belonging to [M 
+ Na]+), and at m/z 1354.8 (presumably an impurity). The second run gave a 70% yield. 
There were the same three peaks but with different ratios (MS-9). 
There are two possible reasons for the existence of the [M + Na]+ peak in the ES-MS 
spectrum. This polar molecule may trap Na+ present in the mass spectrometer during 
ionization. Another reason was related to the work-up method. In the first cyclization, 
NaHCO3 was first used to remove the linear peptide and water-soluble impurities, and 
then KHSO4 was added to remove the remaining linear peptide and water-soluble 
impurities. For the second cyclization, KHSO4 was used first, and NaHCO3 followed. 
Only a [M + Na]+ but no [M + K]+ peak was observed on MS-6 and MS-9. It may 
indicate that the size of the hollow crevice of the cyclic peptide fits the diameter of 
sodium cation well, but not that of potassium ion. 
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Chapter 4   Experimental 
 
4. 1 Materials 
ChiroCLEC-BL subtilisin was purchased from Altus Biologics, amanoacylase from 
Aldrich, and (±)-Z-α-phosphonoglycine trimethyl ester from Fluka. Boc-D-Ala-PAM 
resin, Fmoc-Phe-Wang resin, various commercial amino acids and coupling reagents 
including 1-hydroxybenzo- triazole (HOBT) and benzotriazol-1-yloxytrispyrrolidino-
phosphonium hexafluorophosphate (PyBOP) were purchased from NovaBioChem and 
Advanced ChemTech, and 1-hydroxy-9-azabenzotriazole (HOAT) and O-(7-
azabenzotriazol-1-yl)-N,N,N’,N’ -tetramethyluronium-hexafluoro phosphate (HATU) 
from Aldrich. The other reagents were purchased from Aldrich. All dry solvents were 
purchased from Aldrich and used without further purification. The other solvents were 
purchased from Aldrich or VWR. 
 
4. 2 Analyses and peptide syntheses 
Proton nuclear magnetic resonance (1H NMR) spectra were recorded on a Bruker 
Avance 400 (400 MHz) NMR spectrometer. Unless otherwise noted, spectra were 
recorded in CDCl3. Chemical shifts are reported in ppm (δ) relative to internal 
tetramethylsilane (TMS) at 0.00 ppm. Carbon nuclear magnetic resonance spectra (13C 
NMR) were recorded on the same spectrometer at 100 MHz. Melting points were 
determined on a Thomas-Hoover Capillary melting point apparatus and are uncorrected. 
Analytal thin layer chromatography was performed using precoated silica gel plates 
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(Whatman, KF6F, silica gel 60A, 250 µm; KCF18, silica gel 60A, 200 µm; Sorbtech, 
CHIRALPLATE 25, RP silica gel coated with Cu2+ and a chiral ligand on glass) with a 
254 nm fluorescence indicator. The plates were visualized under a UV lamp, with a PMA 
stain (5 wt % phosphomolybdic acid in EtOH), ninhydrin spray (2 wt % ninhydrin in 1-
butanol) or I2. Wet normal-phase flash column chromatography was performed on 
Mallinckrodt Baker 40 µm silica gel under a positive air pressure. Dry reverse-phase 
flash column chromatography was performed on octadecyl-functionalized silica gel under 
negative pressure. Manual peptide syntheses were carried out in a QPE-3 peptide 
synthesis vessel (supplied by Quark Glass).  ES-MS spectra were provided by Synpep 
Corporation. 
 
4. 3 Dye tests35,36 
The following tests were used to monitor completion of the coupling reaction in solid-
phase peptide synthesis. 
 
Kaiser test (for primary amines) 
• Dissolve5 g of ninhydrin in 100 mL of EtOH 
• Dissolve 80 g of phenol in 20 mL of EtOH 
• Add 2 mL of 1 mmol aqueous KCN to 98 mL of pyridine 
• Sample a few resin beads and wash several times with EtOH 
• Transfer to a small glass tube and add 2 drops of each of the above solutions 
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• Mix well and heat to 120 ºC for 4-6 min. A positive test is indicated by formation 
of blue colored beads. 
 
TNBS test (for hindered primary amines) 
• Make a 10% DIPEA solution in DMF 
• Make a 1% 2,4,6-trinitrobenzenesulfonic acid (TNBS) solution in DMF 
• Sample a few resin beads and wash several times with EtOH 
• Suspend the beads in DMF and add 2 drops of each of the solutions above and 
leave for 5 min 
• Wash the beads with DMF to remove the red solution. A positive test is indicated 
by formation of red colored beads. 
 
Chloranil test (for secondary amines) 
• To 1-5 mg of resin, add one drop of 2% acetaldehyde in DMF followed by one 
drop of 2% p-chloranil in DMF 
• Allow to stand at rt for 5 min. Blue colored beads indicate the presence of 
secondary amines. 
 
4. 4 Dry flash column chromatography18 
The practical approach is fully described in reference 18. 
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4. 5 Syntheses of chromophore-modified chiral amino acids 
The following sections described the details of the experiments. 
 
4. 5. 1 Synthesis of N-Boc-3-(9-anthryl)-L-alanine (Schemes 3-1 and 3-2) 
 
9-Chloromethylanthracene (1). To a stirred solution of 9-anthracenemethanol (2.08 g, 
10 mmol) in 20 mL of dry THF under N2, was added dry pyridine (1.2 mL, 14 mmol), 
giving a yellow solution. After the solution was cooled to 0 °C, SOCl2 (1 mL, 13.4 
mmol) was added dropwise to the flask. The mixture was allowed to return to rt, and 
heated to reflux for four hours. The solvent was removed on a rotary evaporator. The 
crude product was washed with MeOH in order to remove the residual 9-
anthracenemethanol, and recrystallized from CH2Cl2 twice to afford the yellow, long 
needle-like solid 1 (1.48g, 65%): mp 137-139 °C (lit.53 138-140 °C); 1H NMR δ 5.61 (s, 
2H, CH2), 7.51 (t, 2H, J = 4.1 Hz, ArH), 7.60 (t, 2H, J = 5.1 Hz, ArH), 8.02 (d, 2H, J = 
8.5 Hz, ArH), 8.30 (d, 2H, J = 8.9 Hz, ArH), 8.48 (s, 1H, ArH); 13C NMR (not available). 
Diethyl 9-anthrylmethylacetamidomalonate (2). Diethyl acetamidomalonate (1.42 g, 
6.5 mmol), NaH (0.24 g, 10 mmol) and LiBr (0.43 g, 5 mmol) were placed into a dry, N2-
purged three-neck flask immersed in an ice-bath. Dry THF (10 mL) was dropped in 
slowly with stirring, followed by dry EtOH (0.19 mL). After one hour, 1 (1.47 g, 6.5 
mmol) in dry THF (10 mL) was added and the ice-bath was removed. The mixture was 
heated to reflux for 18 hr. The progress of the reaction was followed by reverse-phase 
TLC (EtOH/H2O 4:1, Rf 0.7). The solvent was removed on a rotary evaporator. The crude 
product was dissolved in hot EtOH, and insoluble impurities were removed by filtration. 
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The EtOH was removed on a rotary evaporator. No further purification was done. The 
product was dried in vacuum to give 2 as a yellow solid (1.85 g, 70%): mp (not 
available); 1H NMR (DMSO-d6) δ 1.11 (t, 6H, J = 6.9 Hz, CH3), 1.70 (s, 3H, CH3), 3.55 
(s, 1H, NH), 3.98 (m, 4H, CH2), 4.57 (s, 2H, CH2), 7.50 (m, 4H, ArH), 8.07 (m, 4H, 
ArH), 8.54 (s, 1H, ArH); 13C NMR (not available). 
N-Acetyl-3-(9-anthryl)-DL-alanine (3). Compound 2 (1.84 g, 4.6 mmol) was mixed 
with NaOH (0.74 g, 18.4 mmol) in 20% aq. EtOH solution (75 mL) with stirring. After 
the solution was heated to reflux for four hours, the EtOH was removed on a rotary 
evaporator. Then HCl (3 M, 6.1 mL) was added. The suspension was heated to reflux 
overnight. The resultant precipitate was isolated by filtration and dissolved in NaOH 
solution (0.2 M, 100 mL).  The solution was extracted with EtOAc (3 × 80 mL). The 
organic phase was discarded. The aqueous phase was adjusted to pH 4 with HCl (3 M), 
and then extracted with EtOAc (5 × 250 mL). The combined organic phase was washed 
with brine, and dried over Na2SO4. The solvent was removed on a rotary evaporator. The 
product 3 was a light yellow solid (1.18 g, 85%): mp 265-7 °C (lit.20 269-70 °C); 1H 
NMR (DMSO-d6) δ 1.50 (s, 3H, CH3), 3.76 (m, 1H, CH2), 3.90 (m, 1H, CH2), 4.44 (m, 
1H, CH), 7.38 (m, 4H, ArH), 7.91 (d, 2H, J = 8.2 Hz, ArH), 8.24 (d, 2H, J = 8.7 Hz, 
ArH), 8.28 (d, 1H, J = 8.2 Hz, NH), 8.36 (s, 1H, ArH), 12.8 (s, 0.6H, OH); 13C NMR (not 
available). 
N-Acetyl-3-(9-anthryl)-DL-alanine methyl ester (4). To a solution of 3 (1.15 g, 3.7 
mmol) in dry MeOH (35 mL) was added dropwise BF3· Et2O (1.15 g, 8 mmol) under N2. 
The solution was heated to reflux for two hours. The solvent was removed on a rotary 
evaporator. The crude product was dissolved in EtOAc. The organic phase was washed 
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with 5% of Na2CO3, saturated NH4Cl and brine, and dried over Na2SO4. The solvent was 
removed on a rotary evaporator. The crude product was purified by normal-phase column 
chromatography (hexane/EtOAc 1:1) to afford 4 as a yellow solid (0.9 g, 75%): mp 205-7 
°C (lit.20 208-9 °C); 1H NMR (DMSO-d6) δ 1.68 (s, 3H, CH3), 3.25 (s, 3H, CH3), 3.92 
(m, 1H, CH2), 4.01 (m, 1H, CH2), 4.55 (m, 1H, J = 7.5 Hz, CH), 7.49 (m, 4H, ArH), 8.02 
(d, 2H, J = 8.1 Hz, ArH), 8.21 (d, 2H, J = 8.7 Hz, ArH), 8.48 (s, 1H, ArH), 8.56 (d, 1H, J 
= 7.7 Hz, NH); 13C NMR δ 23.5 (CH3), 30.1 (CH2), 52.7 (OCH3), 53.9 (CH), 124.3 (CH), 
125.3 (CH), 126.6 (CH), 127.6 (CH), 128.5 (C), 129.7 (CH), 131.0 (C), 131.8 (C), 170.2 
(C=O), 173.0 (C=O). 
N-Acetyl-3-(9-anthryl)-L-alanine (5). Compound 4 (880 mg, 2.7 mmol) was mixed with 
DMF (40 mL) and phosphate buffer (0.5 M, pH 7.5, 25 mL). ChiroCLEC-BL (40 mg) 
was added with stirring under N2. The mixture was heated to 60 °C for 72 hr. The 
progress of the reaction was followed by reverse-phase TLC. It was observed that the size 
of a new spot (EtOH/H2O 4:1, Rf 0.90) assigned to 5 became larger with time. The 
enzyme was removed by centrifugation and the solvents were removed on a rotary 
evaporator. The residue was brought to pH 4, and extracted with EtOAc (3 × 200 mL). 
The organic phase was washed with brine, and dried over Na2SO4. The solvent was 
removed on a rotary evaporator. The 1H NMR spectrum of the crude product showed that 
there were two methyl signals, assigned to the acetyl CH3 groups, one belonging to 4 at 
δ 1.69, the other belonging to 5 at δ 1.67 (NMR-8). The ratio of the integrals was 6:4, 
which meant that 40% of 4 had been converted into 5 (yield 80%). Aq. Na2CO3 (5%) was 
added to the mixture, and undissolved 4 extracted into EtOAc (3 × 200 mL). The organic 
phase was washed with brine and dried over Na2SO4. The solvent was removed on a 
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rotary evaporator to yield 4 (520 mg). The aqueous phase was adjusted to pH 4, and 
extracted with EtOAc (5 × 200 mL). The organic phase was washed with brine and dried 
over Na2SO4. The solvent was removed on a rotary evaporator to give 5 as a light yellow 
solid (340 mg, 40%): mp (not available); 1H NMR (DMSO-d6) δ 1.66 (s, 3H, CH3), 3.92 
(m, 1H, CH2), 4.06 (m, 1H, CH2), 4.59 (m, 1H, CH), 7.57 (m, 4H, ArH), 8.10 (d, 2H, J = 
8.2 Hz, ArH), 8.42 (d, 2H, J = 8.8 Hz, ArH), 8.52 (s, 1H, ArH); 13C NMR (DMSO-d6) δ 
22.7 (CH3), 30.1 (CH2), 54.2 (CH), 124.8 (CH), 125.3 (CH), 126.2 (CH), 126.7 (CH), 
129.3 (C), 130.3 (CH), 130.9 (C), 131.4 (C), 169.4 (C=O), 173.6 (C=O). 
9-Anthryl-L-alanine hydrochloride (6a) from acid-catalyzed hydrolysis of 5. 
Compound 5 (180 mg, 0.59 mmol) was suspended in conc. HCl (6 mL) and AcOH (2 
mL). The mixture was heated to reflux overnight. The solvent was removed on a rotary 
evaporator. The product 6a was dried in vacuum to give a brownish yellow solid (174 
mg, positive ninhydrin test). The other analytical data are not available. 
9-Anthryl-L-alanine hydrochloride (6b) from enzyme-catalyzed hydrolysis of 5. 
Compound 5 (150 mg, 0.49 mmol) was dissolved in KOH (1 M), and then HCl (2 M) and 
a small amount of H2O were added to adjust the pH to 7.8. The final concentration of the 
substrate was kept close to 0.05M. CoCl2 (2 mg, 0.05 M) and amanoacylase (5 mg) were 
added. The mixture was set on a shaker at 200 rpm at 37 °C for 48 hr. A yellow 
precipitate was observed. A positive ninhydrin test was shown on normal-phase TLC 
(CHCl3/MeOH/ AcOH 9:1:0.1). The precipitate was isolated by filtration and washed 
with H2O. It was dissolved in EtOH and a small amount of HCl solution (1M) was added 
to dissolve the desired product completely. The insoluble residue was separated. The 
filtrate was heated to 50 °C with a small amount of charcoal in order to denature the 
 67 
amanoacylase. The charcoal was removed by passing the solution through a short column 
filled with Celite. The solvent was evaporated to afford the product 6b as a light yellow 
solid (116 mg, 89%, positive ninhydrin test). The other analytical data are not available. 
N-t-Butyloxycarbonyl-3-(9-anthryl)-L-alanine (7). To a solution of 6a (100 mg, 0.38 
mmol) in dry DMF (2 mL) were added Et3N (0.8 mL) and (Boc)2O (82 mg, 0.38 mmol). 
The mixture was stirred at rt overnight. The solvent was removed on a rotary evaporator. 
The residue was dissolved in EtOAc. The solution was washed with 5% aq. citric acid 
and brine, and dried over Na2SO4. The solvent was removed on a rotary evaporator to 
give 7 as a yellow solid (60 mg, 45%): mp 186-189 °C; 1H NMR (DMSO-d6) δ 0.94 (s, 
9H, CH3), 3.87 (m, 2H, CH2), 4.07 (t, 1H, CH), 7.37 (m, 4H, ArH), 7.89 (d, 2H, J = 8.1 
Hz, ArH), 8.24 (d, 2H, J = 7.9 Hz, ArH), 8.26 (s, 1H, ArH); 13C NMR (not available). 
Diethyl 9-anthrylmethyl-N-(t-butyloxycarbonyl)aminomalonate (8). A three-neck 
flask purged with N2 was charged with NaH (0.2 g, 8.3 mmol) and LiBr (0.37g, 4.2 
mmol) in an ice-bath. Dry DMF (10 mL) was added with stirring, and then diethyl N-(t-
butyloxycarbonyl)-aminomalonate (1.7 g, 6.1 mmol) was slowly added. Dry EtOH (0.24 
mL) was added dropwise. After one hour, a solution of 9-chloromethylanthracene (1.2 g, 
5.3 mmol) in dry THF (10 mL) was added, and the ice-bath was removed. The solution 
was heated to 90 °C for 18 hr. The solvent was removed on a rotary evaporator. The 
residue was dissolved in EtOAc, and washed with aq. citric acid (5%) and brine. The 
solvent was dried over Na2SO4, and then removed on a rotary evaporator. The product 8 
was obtained as a yellow solid (1.32 g, 54%): mp (not available); 1H NMR δ 1.32 (t, 6H, 
J = 7.0 Hz, CH3), 1.49 (s, 9H, CH3), 4.03-4.18 (m, 4H, CH2), 4.73 (s, 2H, CH2), 5.47 (s, 
1H, NH), 7.48 (m, 4H, ArH), 8.01 (d, 2H, J = 5.3 Hz, ArH), 8.30 (d, 2H, J = 4.1, ArH), 
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8.40 (s, 1H, ArH); 13C NMR δ 14.2 (CH3), 28.7 (CH3), 30.6 (CH2), 62.8 (CH2), 67.8 (C), 
125.1 (CH), 125.2 (CH), 125.8 (CH), 127.9 (CH), 128.1 (C), 129.4 (CH), 131.8 (C), 
132.0 (C), 154.7 (C=O), 168.4 (C=O). 
3-(9-Anthryl)-DL-alanine hydrochloride (6) from hydrolysis, decarboxylation and 
Boc deprotection of 8. Compound 8 (1.3 g, 2.8 mmol) was mixed with NaOH (0.45 g, 
11.2 mmol) in 20% aq. EtOH solution (50 mL). The mixture was heated to reflux for four 
hours. The EtOH was removed on a rotary evaporator and then HCl (3 M, 3.7 mL) was 
added. The mixture was heated to reflux overnight, and a yellow precipitate was formed. 
The precipitate was collected to give 6 as a light yellow solid (0.7 g, 95%, positive 
ninhydrin test). The other analytical data are not available. 
3-(9-Anthryl)-DL-alanine methyl ester (9). To a solution of 6 (0.69 g, 2.6 mmol) in dry 
MeOH (20 mL) under N2, cooled in an ice-bath, SOCl2 (0.29 mL, 3.9 mmol) was added 
dropwise. The mixture was heated to reflux overnight. The solvent was removed on a 
rotary evaporator. The residue was dissolved in EtOAc (250 mL). The organic phase was 
washed with 5% aq. Na2CO3 and brine, and dried over Na2SO4. The solvent was removed 
on a rotary evaporator. The crude product was purified by normal-phase column 
chromatography (hexane/EtOAc 1:2.5). Compound 9 (0.5 g, 68%), was obtained as an 
oily yellow solid: mp 180 •C dec; 1H NMR δ 1.62 (s, 2H, NH2), 3.63 (s, 3H, CH3), 3.94 
(m, 1H, CH2), 4.10 (m, 1H, CH2), 4.17 (m, 1H, CH), 7.50-7.57 (m, 4H, ArH), 8.05 (d, 
2H, J = 8.3 Hz, ArH), 8.35 (d, 2H, J = 8.9 Hz, ArH), 8.43 (s, 1H, ArH); 13C NMR (not 
available). 
N-t-Butyloxycarbonyl-3-(9-anthryl)-DL-alanine methyl ester (10) from Boc-
protection of 9. To a stirred solution of 9 (0.48 g, 1.7 mmol) in dry DMF (5 mL) were 
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added Et3N (2 mL) and (BOC)2O (0.6 g, 2.7 mmol). The mixture was stirred at rt 
overnight. The solvent was removed on a rotary evaporator. The residue was dissolved in 
EtOAc (200 mL). The organic phase was washed with 5% aq. citric acid and brine, and 
dried over Na2SO4. The solvent was removed on a rotary evaporator. The crude product 
was further purified by normal-phase column chromatography (hexane/EtOAc 3:1). 
Compound 10 was obtained as a yellow solid (0.49 g, 75%): mp 190-193 °C; 1H NMR δ 
1.29 (s, 9H, CH3), 3.28 (s, 3H, CH3), 3.99 (m, 1H, CH2), 4.04 (m, 1H, CH2), 4.67 (t, 1H, 
CH), 5.22 (s, 1H, NH), 7.48 (m, 4H, ArH), 7.95 (d, 2H, J = 8.3 Hz, ArH), 8.24 (d, 2H, J 
= 7.1 Hz, ArH), 8.33 (s, 1H, ArH); 13C NMR (not available). 
N-t-Butyloxycarbonyl-3-(9-anthryl)-DL-alanine (11). Compound 8 (1.2 g, 2.6 mmol) 
was mixed with NaOH (0.42 g, 10.4 mmol) in 20% aq. EtOH solution (46 ml) with 
stirring. The mixture was heated to reflux for four hours. The EtOH was removed on a 
rotary evaporator, then HCl (1 M) was added slowly and the pH adjusted to 4. The 
formed precipitate was collected by filtration, and then dissolved in dioxane. The dioxane 
solution was heated to reflux for five hours. The solvent was removed on a rotary 
evaporator. The residue was dissolved in EtOAc, washed with brine, and dried over 
Na2SO4. The crude product was purified by normal-phase column chromatography 
(CHCl3/MeOH 9:1) to give 11 as a light yellow solid (0.82 g, 88%): mp (not available); 
1H NMR (DMSO-d6) δ 0.94 (s, 9H, CH3), 3.87 (m, 2H, CH2), 4.07 (m, 1H, CH), 7.37 (m, 
4H, ArH), 7.89 (d, 2H, J = 8.1 Hz, ArH), 8.26 (d, 2H, J = 7.9 Hz, ArH), 8.30 (s, 1H, 
ArH); 13C NMR (not available). 
N-t-Butyloxycarbonyl-3-(9-anthryl)-DL-alanine methyl ester (10) from methyl 
esterification of 11. To a solution of 11 (0.8 g, 2.2 mmol) in dry MeOH (20 mL), was 
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added dropwise trimethylsilyldiazomethane (2.2 mL, 2 M in hexane, 4.4 mmol) with 
stirring at rt under N2 for five hours. The solvent was removed on a rotary evaporator. 
The residue was dissolved in EtOAc (50 mL), washed with 5% aq. citric acid and brine, 
and dried over Na2SO4. The solvent was removed on a rotary evaporator. The crude 
product was purified by normal-phase column chromatography (hexane/EtOAc 3:1) to 
give 10 as a yellow solid (0.55 g, 70%): mp 191-193 oC; 1H NMR δ 1.40 (s, 9H, CH3), 
3.33 (s, 3H, CH3), 4.04 (m, 1H, CH2), 4.07 (m, 1H, CH2), 4.78 (t, 1H, J = 7.1 Hz, CH), 
5.30 (s, 1H, NH), 7.50 (m, 2H, ArH), 7.58 (m, 2H, ArH), 7.95 (d, 2H, J = 8.3 Hz, ArH), 
8.33 (d, 2H, J = 8.6 Hz, ArH), 8.43 (s, 1H, ArH); 13C NMR (not available). 
N-t-Butyloxycarbonyl-3-(9-anthryl)-L-alanine (7) from enzyme-catalyzed hydrolysis 
of 10. Compound 10 (500 mg, 1.3 mmol) was suspended in DMF (30 mL) and phosphate 
buffer (0.5 M, pH 7.5, 15 mL). ChiroCLEC-BL (40 mg) was added with stirring at 60 °C 
for 72 hr. The progress of the reaction was followed by reverse-phase TLC. A new spot 
with Rf 0.9 (reverse-phase TLC, EtOH/H2O 4:1) increased with time. The enzyme was 
removed by centrifugation and the solvents were removed on a rotary evaporator. The 
residue was dissolved in EtOAc (200 mL). The organic phase was washed with 5% aq. 
NaHCO3 (3 × 50 mL), washed with brine, and dried over Na2SO4. The solvent was 
removed on a rotary evaporator to recover 10 (460 mg). The aqueous phase was brought 
to pH 4, and extracted with EtOAc (5 × 200 mL). The organic phase was washed with 
brine and dried over Na2SO4. The solvent was removed on a rotary evaporator to give 7 
as a light yellow solid (20 mg, 8%). The analytical data are not available. 
Attempted enzyme-catalyzed hydrolysis of 3-(9-anthryl)-DL-alanine methyl ester 
trifluoroacetate (12). Compound 10 (100 mg, 0.26 mmol) was mixed with TFA (5 mL) 
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and CH2Cl2 (5 mL) with stirring for 30 min in an ice-bath. The solvents were completely 
removed on a rotary evaporator to give the intermediate 12. Compound 12 was dissolved 
in DMF (7 mL) and phosphate buffer (0.5 M, pH 7.5, 3 mL). ChiroCLEC-BL (10 mg) 
was added and the mixture stirred at 60 °C for 72 hr. The progress of the reaction was 
followed by normal-phase TLC (CHCl3/MeOH/AcOH 5:1:0.1, visualized by UV lamp 
and ninhydrin spray), which showed that the conversion was less than 20%, and several 
side products had been formed. No further purification was carried out. 
 
4. 5. 2 Synthesis of N-ethylcarbazolyl-L-alanine and its derivatives (Schemes 3-3 and 
3-4) 
 
N-Ethyl-3-hydroxymethyl carbazole (13).54 N-Ethyl-3-carbazolecarboxaldehyde (2.24 
g, 10 mmol) was dissolved in MeOH containing 2% NaOH (50 mL). NaBH4 (0.21 g, 5.5 
mmol) was added, and the solution was kept at rt overnight. The reaction mixture was 
diluted with H2O and extracted with benzene (3 × 100 mL). The organic phase was dried 
over Na2SO4. The solvent was removed on a rotary evaporator. The crude product was 
recrystallized twice from EtOH at -10 °C, giving white, felt-like needles 13 (1.57 g, 
70%): mp 75-76 oC (lit.54 75-76 oC); 1H NMR (DMSO-d6 + D2O) δ 1.28 (t, 3H, J = 7.1 
Hz, CH3), 4.42 (m, 2H, CH2), 4.63 (s, 2H, CH2), 5.15 (s, 0.7H, OH), 7.18 (t, 1H, J = 7.4 
Hz, ArH), 7.42 (t, 1H, J = 7.4 Hz, ArH), 7.44 (d, 1H, J = 7.6 Hz, ArH), 7.55 (d, 2H, J = 
8.2 Hz, ArH), 8.00 (s, 1H, ArH), 8.10 (d, 1H, J = 7.7 Hz, ArH); 13C NMR (not available). 
Attempted synthesis of N-ethyl-3-chloromethylcarbazole. To a solution of 13 (1.55 g, 
6.9 mmol) in dry THF (20 mL), was added dry pyridine (1.2 mL, 14 mmol) with stirring 
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under N2.  After the mixture was cooled to 0 °C, SOCl2 (1 mL, 13.4 mmol) was added 
dropwise. The mixture was allowed to return to rt and the solution turned blue slowly. No 
further work-up was undertaken. 
4-(3-(N-Ethylcarbazolylidene))-2-phenyloxazol-5-one (14). A stirred mixture of 9-
ethyl-3-carbazolecarboxaldehyde (1.12 g, 5 mmol), powdered, dry hippuric acid (0.9 g, 5 
mmol), and powdered, freshly fused NaOAc (1.2 g, 15 mmol) in Ac2O (10 mL) was 
heated to reflux for four hours. A deep yellow precipitate was observed and then hot 
EtOH (15 mL) was added into the flask. During the addition, the round-bottom flask was 
slightly cooled. After the reaction mixture was allowed to stand overnight, the crystalline 
product was collected by filtration and washed with ice-cold EtOH twice and boiling 
water twice to give 14 as a bright yellow solid (1.28 g, 70%): mp (not available); 1H 
NMR δ 1.45 (t, 3H, J = 7.2 Hz, CH3), 4.37 (q, 2H, J = 7.2 Hz, CH2), 7.32 (t, 1H, ArH), 
7.47 (m, 3H, ArH, =CH), 7.55 (m, 4H, ArH), 8.17 (m, 3H, ArH), 8.39 (d, 1H, ArH), 8.93 
(s, 1H, ArH); 13C NMR (not available). 
N-Benzoyl-3-(N’-ethyl-3-carbazolyl)acrylic acid (15). Compound 14 (1.2g, 3.3 mmol) 
was suspended in EtOH (30 mL). The suspension was heated until the solid dissolved. 
NaOH (0.5 M, 20 mL) was added and the mixture was heaed to reflux for two hours. The 
solution turned light yellow. H2O (30 mL) was added and the EtOH was removed on a 
rotary evaporator. When HCl (6 M, 2 mL) was slowly added to the residue, a light yellow 
precipitate was formed. The mixture was kept at an ice-bath for 30 min. The precipitate 
was collected by filtration, washed with H2O, and dried in vacuum to give 15 as a light 
yellow solid (1.16 g, 90%): mp (not available); 1H NMR (DMSO-d6) δ 1.33 (t, 3H, J = 
7.4 Hz, CH3), 4.44 (q, 2H, J = 6.6 Hz, CH2), 7.23 (t, 1H, J = 7.3 Hz, ArH), 7.49 (t, 1H, J 
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= 7.4 Hz, ArH), 7.62 (m, 5H, ArH), 7.85 (d, 2H, J = 7.3 Hz, ArH), 7.64 (s, 1H, =CH), 
7.98 (d, 1H, J = 7.6 Hz, ArH), 8.07 (d, 1H, J = 7.2 Hz, ArH), 8.50 (s, 1H, NH), 12.66 (s, 
1H, OH); 13C NMR (not available). 
N-Benzoyl-3-(N’-ethyl-3-carbazolyl)alanine (16). To a solution of 15 (1.0 g, 2.6 mmol) 
in THF (30 mL) was added 10% Pd-C catalyst (100 mg). The mixture was shaken on a 
Parr shaker (30-40 psi) for 48 hr. The catalyst was removed by filtration through a pad of 
Celite and the solvent was removed on a rotary evaporator. The residue was dissolved in 
hot NaOH (0.2 M, 15 mL). When HCl (3 M, 1 mL) was slowly dropped into the solution, 
a white precipitate was formed. The precipitate was collected by filtration and dissolved 
in EtOAc (200 mL). The organic phase was washed with brine and dried over Na2SO4. 
The solvent was removed on a rotary evaporator to give 16 as a white solid (0.95 g, 
95%): mp (not available); 1H NMR (DMSO-d6) δ 1.26 (t, 3H, J = 7.0 Hz, CH3), 3.21 (m, 
1H, CH2), 3.36 (m, 1H, CH2), 4.38 (m, 2H, CH2), 4.69 (m, 1H, CH), 7.15 (t, 1H, J = 7.6 
Hz, ArH), 7.42 (m, 3H, ArH), 7.47 (d, 2H, J = 7.7 Hz, ArH), 7.52 (d, 1H, J = 8.2 Hz, 
ArH), 7.77 (d, 2H, J = 7.1 Hz, ArH), 8.04 (d, 2H, J = 8.3 Hz, ArH), 8.76 (d, 1H, J = 8.1 
Hz, ArH), 12.7 (s, 1H, OH); 13C NMR (not available). 
Attempted acid-catalyzed hydrolysis of 16. Compound 16 (400 mg, 1.0 mmol) was 
suspended in a mixture of HCl (6 M, 15 mL) and AcOH (7 mL). The mixture was heated 
to reflux. The solution turned blue after three hours. The blue color disappeared when the 
solution was made basic with NaOH (0.2 M), and came back again when the pH was 
adjusted to 4 with HCl (1 M). Then the mixture was extracted with EtOAc (2 × 50 mL). 
The organic solutions were combined and the solvent was removed on a rotary 
evaporator. The NMR spectrum of the blue residue was similar to that of the starting 
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material, except that the relative integration of the aromatic protons was slightly reduced. 
The other analytical data are not available. 
Attempted one-pot synthesis of 3-(N-ethyl-3-carbazolyl)-DL-alanine from 14. To a 
solution of 14 (1.0 g, 2.7 mmol) in Ac2O (5 mL) was added red phosphorus (0.6 g, 19 
mmol) and HI (47%, 4 mL, dropwise). The mixture was heated to 140-150 °C for six 
hours. The progress of the reaction was followed by normal-phase TLC (CHCl3/MeOH/ 
AcOH 5:1:0.1). Several new spots with positive ninhydrin tests were observed on TLC. 
The desired product couldn’t be clearly isolated from the other side products due to their 
similar Rf values. The other analytical data are not available. 
Methyl 2-amino-2-(dimethoxyphosphonyl)acetate (17).51 A solution of (±)-Z-α-
phosphono-glycine trimethyl ester (1.5 g, 4.5 mmol) in MeOH (25 mL) was mixed with 
10% Pd-C (0.1 g) with stirring under a H2-filled balloon for 24 hr.  The catalyst was 
removed by filtration through a short column filled with Celite. The filtrate was 
concentrated to give 17 as a transparent solid (0.8 g, 90%). The analytical data are not 
available. 
Methyl 2-(t-butoxycarbonylamino)-2-(dimethoxyphosphonyl)acetate (18).51 To a 
stirred solution of 17 (0.8 g, 4.1 mmol) and di-t-butyldicarbonate (1.2 g, 5.5 mmol) in 
CH2Cl2 (20 mL) was added pyridine (0.3 mL, 4.1 mmol) at rt. The mixture was stirred for 
48 hr. The solvent was removed on a rotary evaporator, and the residue dissolved in 
EtOAc (50 mL). The solution was washed with 5% aq. citric acid, saturated Na2CO3 and 
brine, and dried over Na2SO4. The solvent was removed on a rotary evaporator. The 
residue was purified by normal-phase column chromatography (hexane/EtOAc 1:5) to 
give a semi-transparent solid (1.0 g, 83%): mp 44-46 °C (lit.51 44-46 °C); 1H NMR δ 1.50 
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(s, 9H, CH3), 3.81 (d, 6H, J = 4.0, CH3), 3.85 (s, 3H, CH3), 4.86-4.94 (m, 1H, CH), 5.37 
(d, 1H, NH); 13C NMR δ 28.6 (CH3), 51.3 (OCH3), 52.7 (OCH3), 53.7 (OCH3), 54.6 
(CH), 81.4 (C), 167.9 (C=O). 
Methyl 2-acetamino-2-(dimethoxyphosphonyl)acetate (19).50  A solution of (±)-Z-α-
phosphonoglycine trimethyl ester (4.9 g, 14.8 mmol) in MeOH (75 mL) was mixed with 
10% Pd-C (0.5 g) and Ac2O (4 mL) with stirring for 24 hr under a H2 atmosphere 
maintained with a balloon. The catalyst was removed by filtration through a short column 
filled with Celite. The solvent was removed on a rotary evaporator and hexane was added 
to aid in the crystallization. The mixture was stored in a refrigerator overnight. The 
product was collected by filtration, giving 19 as a semi-transparent solid (3.3 g, 93%): mp 
85-87 ºC (lit.51 85-87 °C); 1H NMR δ 1.98 (s, 3H, CH3), 3.83 (d, 6H, J = 2.8, CH3), 3,85 
(s, 3H, CH3), 5.07-5.17 (m, 1H, CH), 6.30 (d, 1H, NH); 13C NMR δ 23.3 (CH3), 49.6 
(OCH3), 51.1 (OCH3), 53.8 (OCH3), 54.7 (CH), 167.6 (C=O), 170.0 (C=O). 
N-t-Butoxycarbonyl-3-(N’-ethyl-3-carbazolyl)-DL-acryl acid methyl ester (20a). To a 
stirred solution of 18 (0.8 g, 2.7 mmol) in dry THF (10 mL) was added 1,1,3,3-
tetramethyl-guanidine (0.35 mL, 2.8 mmol) dropwise at -70 °C. N-Ethyl-3-carbazole- 
carboxaldehyde (0.6 g, 2.7 mmol) in dry THF (7 mL) was added slowly. The mixture was 
kept at -70 °C for one hour and then warmed to rt and stirred overnight. The progress of 
the reaction was followed by normal-phase TLC (hexane/EtOAc 1:3) and two adjacent 
new spots with Rf 0.5 were observed on TLC. Two peaks at δ 1.42 and 0.95 were 
observed by 1H NMR and assigned to CH3 peaks belonging to the E and Z isomers, 
respectively. The solvent was removed on a rotary evaporator. The residue was dissolved 
in EtOAc (200 mL) and the solution was washed with 5% aq. citric acid, H2O and brine, 
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and dried over Na2SO4. The solvent was removed on a rotary evaporator. The crude 
product was purified by normal-phase column chromatography (hexane/EtOAc 1:1), 
giving 20a as a white solid (E,Z mixture, 0.76 g, 71%): mp (not available); 1H NMR δ 
1.39-1.57 (m, 12H, 4CH3), 3.87 (s, 3H, CH3), 4.38 (q, 2H, CH2), 7.25 (t, 1H, J = 7.2 Hz, 
ArH), 7.37 (d, 1H, J = 6.4 Hz, ArH), 7.41 (d, 1H, J = 8.1 Hz, ArH), 7.47 (t, 1H, J = 7.1 
Hz, ArH), 7,57 (s, 1H, =CH), 7.75 (m, 1H, ArH), 8.07 (d, 1H, J = 7.8 Hz, ArH), 8.34 (s, 
1H, NH); 13C NMR (not available). 
N-Acetyl-3-(N’-ethyl-3-carbazolyl)-DL-acrylic acid methyl ester (20b). To a stirred 
solution of 19 (3.2 g, 13.3 mmol) in dry THF (40 mL), cooled to -70 °C, was added 
tetramethylguanidine (1.5 g, 13.3 mmol) dropwise. N-Ethyl-3-carbazolecarboxaldehyde 
(2.7 g, 12 mmol) in dry THF (32 mL) was added slowly. The mixture was kept at -70 °C 
for one hour. The mixture was warmed to rt and stirred overnight. The progress of the 
reaction was followed by normal phase TLC. Two adjacent new spots were observed on 
the TLC plate. The solvent was removed on a rotary evaporator. The residue was 
dissolved in EtOAc (50 mL). The organic phase was washed with 5% aq. citric acid and 
brine, and dried over Na2SO4. The solvent was removed on a rotary evaporator. The 
crude product was purified by normal-phase column chromatography (hexane/EtOAc 
1:3), giving 20b as a white solid (E, Z mixture, 2.6 g, 65%). The peaks at δ 2.15 and 1.85 
observed by NMR, were assigned to CH3 groups belonging to the E and Z isomers, 
respectively. Mp (not available); 1H NMR δ 1.38 (t, 3H, J = 7.2 Hz, CH3), 1.85 (s, 0.6H, 
CH3), 2.15 (s, 2.4H, CH3), 3.87 (s, 3H, CH3), 4.36 (m, 2H, CH2), 6.57 (s, 0.2H, NH), 7.02 
(s, 0.8H, NH), 7.31 (t, 1H, J = 6.8 Hz, ArH), 7.43 (d, 1H, J = 8.1 Hz, ArH), 7.47 (t, 1H, J 
= 7.5 Hz, ArH), 7.51 (d, 1H, J = 7.7 Hz, ArH), 7.65 (s, 0.8H, =CH), 7.69 (d, 0.8H, J = 8.7 
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Hz, ArH), 7.84 (s, 0.2H, =CH), 7.85 (d, 0.2H, ArH), 8.03 (d, 0.8H, J = 7.7 Hz, ArH), 8.05 
(d, 0.2H, ArH), 8.24 (s, 0.8H, ArH), 8.39 (s, 0.2H, ArH); 13C NMR δ 14.3 (CH3), 24.0 
(CH3), 38.1 (CH2), 53.0 (OCH3), 109.0 (=CH), 109.2 (=C), 119.9 (CH), 120.8 (CH), 
121.7 (CH), 123.2 (C), 123.4 (C), 124.7 (C), 126.6 (C), 127.0 (CH), 128.2 (CH), 135.4 
(CH), 140.8 (CH), 141.0 (C), 166.6 (C=O), 169.5 (C=O). 
N-t-Butoxycarbonyl-3-(N’-ethyl-3-carbazolyl)-DL-alanine methyl ester (21a). A 
solution of 20a (0.75 g, 1.9 mmol) in MeOH (15 mL) was mixed with 10% Pd-C (50 mg) 
with stirring under a H2-filled balloon at rt for 24 hr. The catalyst was removed by 
filtration through a column filled with Celite. The filtrate was evaporated to dryness and 
the residue was purified by normal-phase column chromatography (hexane/EtOAc 3:1) to 
give 21a as a white solid (0.69 g, 92%): mp 155-156 °C; 1H NMR δ 1.53 (s, 9H, CH3), 
1.70 (t, 3H, J = 8.3 Hz, CH3), 3.40 (m, 2H, CH2), 3.88 (s, 3H, OCH3), 4.48 (q, 2H, J = 7.2 
Hz, CH2), 4.76 (q, 1H, J = 6.1 Hz, CH), 5.15 (d, 1H, NH), 7.32 (t, 2H, J = 7.7 Hz, ArH), 
7.41 (d, 1H, J = 7.5 Hz, ArH), 7.45 (d, 1H, J = 8.3 Hz, ArH), 7.50 (d, 1H, J = 7.8 Hz, 
ArH), 7.96 (s, 1H, ArH), 8.19 (d, 1H, J = 7.7 Hz, ArH); 13C NMR (not available). 
N-Acetyl-3-(N’-ethyl-3-carbazolyl)-DL-alanine methyl ester (21b). A solution of 20b 
(2.55 g, 7.5 mmol) in MeOH (40 mL) was mixed with 10% Pd-C (0.25 g) with stirring 
under a H2-filled balloon at rt for 48 hr. The catalyst was filtered through a column filled 
with Celite. The filtrate was evaporated to dryness and the residue purified by normal-
phase column chromatography (hexane/EtOAc 1:3) to give 21b as a white solid (2.55 g, 
99%): mp 80 °C; 1H NMR δ 1.45 (t, 3H, J = 7.2 Hz, CH3), 2.06 (s, 3H, CH3), 3.33 (m, 
2H, CH2), 3.77 (s, 3H, CH3), 4.38 (q, 2H, J = 7.2 Hz, CH2), 4.97 (q, 1H, J = 5.8 Hz, CH), 
5.98 (d, 1H, NH), 7.20 (t, 1H, J = 6.7 Hz, ArH), 7.27 (d, 1H, J = 5.8 Hz, ArH), 7.35 (d, 
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1H, J = 8.3 Hz, ArH), 7.42 (d, 1H, J = 8.2 Hz, ArH), 7.48 (t, 1H, J = 6.0 Hz, ArH), 7.84 
(s, 1H, ArH), 8.07 (d, 1H, J = 7.7 Hz, ArH); 13C NMR δ 14.3 (CH3), 23.6 (CH3), 38.0 
(CH2), 38.4 (CH2), 52.7 (CH), 54.2 (OCH3), 108.5 (CH), 108.9 (CH), 116.8 (CH), 121.2 
(C), 122.6 (C), 123.7 (C), 124.2 (C), 125.9 (CH), 126.7 (CH), 138.8 (CH), 139.9 (CH), 
142.3 (C), 170.2 (C=O), 172.9 (C=O). 
N-t-Butoxycarbonyl-3-(N’-ethyl-3-carbazolyl)-L-alanine (22). Compound 21a (160 
mg, 0.42 mmol) was suspended in a solution of DMF (10 mL) and phosphate buffer (0.5 
M, pH 7.7, 8 mL). ChiroCLEC-BL (16 mg) was added. The mixture was stirred at 60 °C 
for 72 hr. The progress of the reaction was followed by reverse-phase TLC. A new spot 
with Rf 0.9 (EtOH/H2O 4:1) became bigger with time. The enzyme was removed by 
centrifugation and the solvents were removed on a rotary evaporator. The base-soluble 
product was dissolved in 5% aq. Na2CO3, and the unhydrolytic starting material was 
extracted with EtOAc. The organic phase was washed with brine and dried over Na2SO4. 
The solvent was removed on a rotary evaporator to give 21a (140 mg). The aqueous 
phase was brought to pH 4 and extracted with EtOAc (5 × 200 mL). The organic phase 
was washed with brine and dried over Na2SO4. The solvent was removed on a rotary 
evaporator to give 22 as a white solid (10 mg, 16%). Better conversion couldn’t be 
achieved by varying the temperature or the solvents. The analytical data are not available. 
N-Acetyl-3-(N’-ethyl-3-carbazolyl)-L-alanine (23). Compound 21b (2.50 g, 7.4 mmol) 
was mixed with acetone (40 mL) and phosphate buffer (0.25 M, pH 7.5, 60 mL). 
ChiroCLEC-BL (80 mg) was added. The mixture was agitated on an orbital shaker at 200 
rpm at 37 °C for 24 hr. The progress of the reaction was followed by reverse-phase TLC 
(EtOH/H2O 4:1, Rf 0.9). The enzyme was removed by centrifugation and the solvents 
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were removed on a rotary evaporator. Then the hydrolyzed product was dissolved in 5% 
aq. Na2CO3, and unhydrolyzed starting material was extracted with EtOAc. The organic 
phase was dried over Na2SO4. The solvent was removed on a rotary evaporator to give 
21b (120 mg, enriched in D-isomer). The aqueous phase was brought to pH 4 and 
extracted with EtOAc (5 × 200 mL). The organic phase was washed with brine and dried 
over Na2SO4. The solvent was removed on a rotary evaporator to give 23 as an off-white 
foam (110 mg, 100%): mp 75 °C; 1H NMR δ 1.40 (t, 3H, J = 7.1 Hz, CH3), 2.05 (s, 3H, 
CH3), 3.35 (m, 2H, CH2), 4.32 (m, 2H, CH2), 4.95 (m, 1H, CH), 6.18 (d, 1H, J = 7.1 Hz, 
NH), 7.20 (t, 1H, J = 7.3 Hz, ArH), 7.26 (d, 1H, J = 5.7 Hz, ArH), 7.32 (d, 1H, J = 8.3 
Hz, ArH), 7.39 (d, 1H, J = 8.1 Hz, ArH), 7.41 (t, 1H, J = 7.2 Hz, ArH), 7.88 (s, 1H, 
ArH), 8.06 (d, 1H, J = 7.7 Hz, ArH) 8.65 (bs, 1H, OH); 13C NMR δ 14.2 (CH3), 23.4 
(CH3), 37.7 (CH2), 38.0 (CH2), 54.3 (CH), 108.9 (CH), 109.1 (CH), 119.2 (CH), 120.7 
(CH), 121.5 (CH), 122.9 (C), 123.5 (C), 126.1 (C), 126.2 (CH), 127.1 (CH), 139.6 (C), 
140.5 (C), 171.4 (C=O), 175.9 (C=O). 
3-(N-Ethyl-3-carbazolyl)-L-alanine (24). Compound 23 (1.20 g, 3.7 mmol) was 
dissolved in NaOH (20 mL, 1 M). Then HCl (2 M) and H2O were added in order to adjust 
the pH to 8 and the final concentration of the substrate to 0.05-0.1 M. Amanoacylase (30 
mg) and CoCl2 (10 mg) were added. The mixture was placed on a shaker at 37 °C for 24 
hr. A light pink precipitate formed. The progress of the reaction was followed by normal-
phase TLC (CHCl3/MeOH/AcOH 5:1:0.1). The spot assigned to 23 (Rf  0.6) almost 
disappeared on the TLC plate and a new spot assigned to 24 (Rf 0.8) gave a positive 
ninhydrin test. The solid was collected by centrifugation and dissolved again in EtOH 
(250 mL) containing HCl (1 M, 5 mL). An insoluble solid was removed by filtration. The 
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filtrate was heated to 50 °C with a small amount of charcoal in order to denature the 
amanoacalyse and the charcoal was removed by filtration thought a short column filled 
with Celite. The solution was evaporated to dryness. A dry reverse-phase flash column 
chromatography (MeCN/H2O/MeOH 2:1:0.5) was carried out and gave 24 as a white 
solid (1.02 g, 97%): mp (not available); 1H NMR (DMSO-d6) δ 1.30 (t, 3H, J = 6.9 Hz, 
CH3), 3.01 (m, 1H, CH2), 3.04 (m, 1H, CH2), 3.06-3.33 (m, 4H, OH, NH2, CH), 4.41 (m, 
2H, CH2), 7.15 (t, 1H, J = 7.4 Hz, ArH), 7.37 (d, 1H, J = 8.3 Hz, ArH), 7.41 (t, 1H, J = 
7.8 Hz, ArH), 7.45 (d, 1H, J = 7.4 Hz, ArH), 7.57 (d, 1H, J = 8.1 Hz, ArH), 7.60 (s, 1H, 
ArH), 8.06 (d, 1H, J = 7.7 Hz, ArH), 12.8 (s, 1H, OH); 13C NMR (DMSO-d6) δ 
13.6(CH3), 36.8(CH2), 38.7(CH3), 56.0(CH), 108.8, 108.9, 118.4, 120.1, 120.8, 121.9, 
122.1, 125.4, 127.2, 127.5, 138.4, 139.6, 169.5(C=O); ES-MS calcd for C17H19N2O2 [M + 
1]+ 283.1, found 283.2. 
N-Fmoc-3-(N’-ethyl-3-carbazolyl)-L-alanine (25). Aq. Na2CO3 (10%, 10 mL) was 
added to 24 (1.0 g, 3.5 mmol), and a small amount of NaHCO3 and H2O were added to 
dissolve the substrate and adjust the pH to 10-11. Then dioxane (10 mL) was added and 
the solution was cooled to 0 °C. Fmoc-OSu (1.1 g, 3.2 mmol) was dissolved in dioxane (5 
mL) and added dropwise. The mixture was stirred at 0 °C for 30 min, and at rt for an 
additional four hours. A white precipitate formed during the reaction. The progress of the 
reaction was followed by normal-phase TLC (CHCl3/MeOH/AcOH 9:1:0.1). Et2O (30 
mL) was added to extract impurities. The aqueous solution was brought to pH 3 and 
extracted with EtOAc. The organic phase was washed with brine and dried over Na2SO4. 
The solvent was removed on a rotary evaporator and the residue was purified by normal-
phase column chromatography (CH2Cl2/MeOH 11:1). The material isolated by 
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chromatography showed two spots close to each other on TLC plate. Further purification 
was done by recrystallization from CHCl3 to give 25 as a pure white powder (0.65 g, 
40%): mp 158-160 °C; 1H NMR (DMSO-d6) δ 1.27 (t, 3H, J = 7.0 Hz, CH3), 3.05 (m, 
1H, CH2), 3.65 (m, 1H, CH2), 4.14 (m, 3H, CH, CH2), 4.17 (m, 1H, CH), 4.41 (m, 2H, 
CH2), 7.15 (m, 2H, ArH), 7.17 (t, 1H, J = 7.4 Hz, ArH), 7.37 (m, 4H, ArH), 7.50 (m, 1H, 
ArH), 7.57 (m, 2H, ArH), 7.84 (d, 2H, J = 7.4 Hz, ArH), 8.06 (s, 1H, ArH), 8.07 (d, 1H, J 
= 3.7 Hz, ArH), 12.8 (s, 1H, OH); 13C NMR (DMSO-d6) δ13.6(CH3), 36.5(CH2), 
36.8(CH2), 46.4 (CH2,), 56.2(CH), 65.5(CH), 108.6, 108.9, 118.4, 119.9, 120.1, 120.5, 
121.8, 121.9, 125.2, 125.5, 126.9, 127.5, 128.1, 138.3, 139.6, 140.5, 143.5, 143.6, 
155.9(C=O), 173.5(C=O); ES-MS calcd for C32H29N2O4 [M + 1]+ 505.2, found 505.4. 
 
4. 6 Solid-phase peptide synthesis 
 
4. 6. 1 4-Mer model peptide by Boc-strategy solid-phase peptide synthesis (26, H-
Car-D-Ala-Bpa-D-Ala-OH) 
 
• Swelling: Boc-D-Ala-PAM resin (0.2 g, 0.16 mmol) was swollen in CH2Cl2 (10 
mL) for one hour with N2 bubbling, and the CH2Cl2 drained. 
• Deprotection: The resin was treated twice with 50% TFA/CH2Cl2 (10 mL) with N2 
bubbling for 30 min. A positive ninhydrin test (blue beads and blue solution) 
indicated the presence of a primary amine. 
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• Washing: The resin was washed with CH2Cl2, 20% DIPEA/CH2Cl2, DMF, MeOH, 
and CH2Cl2 (5 × 10 mL each), the solvents drained and the resin dried in vacuum. 
• Activation and coupling: The coupling reagents (listed in Table 3.1) were mixed in 
a round flask and stirred for 5 min, and then added to the resin with N2 bubbling 
for the indicated period. The negative ninhydrin test signaled complete coupling. 
 
Table 4-1   The quantities of coupling reagents and reaction times for synthesis of 4-mer model peptide 
(26). 
 
Step Coupling reagents Reaction time (hr) 
1 
Boc-4-benzoyl-L-phenylalanine (296 mg, 0.8 mmol), 
PyBOP (416 mg, 0.8 mmol), HOBT (122 mg, 0.8 mmol), 
and DIPEA (0.28 mL) dissolved in DMF (5 mL) 
16 
2 
Boc-D-alanine (151 mg, 0.8 mmol), PyBOP (416 mg, 0.8 
mmol), HOBT (122 mg, 0.8 mmol), and DIPEA (0.28 mL) 
dissolved in DMF (5 mL) 
4 
3 
N-Boc-3-(N’ -ethyl-3-carbazolyl)-L-alanine (191 mg, 0.5 
mmol), PyBOP (260 mg, 0.5 mmol), HOBT (77 mg, 0.5 
mmol), and DIPEA (0.18 mL) dissolved in DMF (3.2 mL) 
18 
 
• Washing after coupling: The solvents were removed and the resin was washed 
with DMF, MeOH, EtOH and CH2Cl2 (5 × 10 mL each), the solvent drained, and 
the resin dried in vacuum. 
• Final washing before cleavage: The resin was washed with DMF, CH2Cl2, MeOH, 
and Et2O (5 × 10 mL each), the solvents drained, and the resin dried in vacuum. It 
weighed 0.22 g. 
• Cleavage: The dry resin was placed into a round-bottom flask. Thiolanisole (0.5 
mL) and ethanedithiol (0.25 mL) were added with stirring for 2 min. After the 
solution was cooled to 0 °C, TFA (5 mL) was dropped in. After 10 min, TFMSA 
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(0.5 mL) was added dropwise. Then the ice-bath was removed and the mixture was 
stirred at rt for 1 hour. After that, the resin was removed on a sintered funnel under 
reduced pressure. The resin was washed with TFA twice. Then cold Et2O (100 
mL) was added into the filtrate, and the mixture was stored in the refrigerator 
overnight. No precipitate was observed. The TFA was removed under vacuum. 
The residue was poured into cold Et2O (100 mL) and the mixture was stored in the 
refrigerator overnight. Again, no precipitate was observed. The solvents were 
evaporated under vacuum (< 80 °C). Finally, a yellow solid-like residue with an 
oily liquid on the surface was obtained. Cold Et2O was used to wash away the oily 
impurity. After filtration and drying, this light yellow solid weighed 0.55 g and 
showed a positive Kaiser test. It was washed with cold Et2O again. It weighed 0.45 
g (> 100% yield). ES-MS calcd for C41H43N5O8, 790.8 [M + 1]+ as a TFA salt, 
found 791.4. 
 
4. 6. 2 8-Mer model peptide by Fmoc-strategy solid-phase peptide synthesis (27, H-
D-Ala-Nap-D-MeAla-Ala-D-Ala-Bpa-D-Ala-Ala-OH) 
 
• Swelling: Fmoc-Ala-Wang resin (0.3 g, 0.18 mmol) was swollen in DMF (10 mL) 
for 1 hour with N2 bubbling, and the CH2Cl2 drained.  
• Deprotection: The resin was treated with 25% piperidine/DMF (10 mL) with N2 
bubbling for 30 min, twice. A positive Kaiser test indicated the presence of a 
primary amine and a positive chloranil test indicated a secondary amine (deep blue 
beads). 
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• Washing: The resin was washed with DMF, CH2Cl2, and DMF (5 × 10 mL each), 
the solvents drained, and dried in vacuum. 
• Activation and coupling: The coupling reagents (listed in Table 4.2) were mixed in 
a round flask and stirred for 5 min, and then added to the resin with N2 bubbling 
for the indicated period. The negative Kaiser or Chloranil test signaled complete 
coupling. 
Table 4-2   The quantities of coupling reagents and reaction times for synthesis of 8-mer model peptide 
(27). 
 
Step Coupling reagents Reaction time (hr) 
1, 3, 7 
Fmoc-D-alanine (280 mg, 0.9 mmol), PyBOP 
(468 mg, 0.9 mmol), HOBT (137 mg, 0.9 mmol),  
and DIPEA (0.31 mL) dissolved in DMF (6 mL) 
4 
2 
Fmoc-4-benzoyl-L-phenylalanine (265 mg, 0.54 mmol), 
PyBOP (281 mg, 0.54 mmol), HOBT (137 mg, 0.54 
mmol), and DIPEA (0.19 mL) dissolved in DMF (3.6 mL) 
16 
4 
Fmoc-alanine (280 mg, 0.9 mmol), PyBOP 
(468 mg, 0.9 mmol), HOBT (137 mg, 0.9 mmol),  
and DIPEA (0.31 mL) dissolved in DMF (6 mL) 
4 
5 
N-Fmoc-N’ -methyl-D-alanine (293 mg, 0.9 mmol), 
PyBOP (468 mg, 0.9 mmol), HOBT (137 mg, 0.9 mmol), 
and DIPEA (0.31 mL) dissolved in DMF (6 mL) 
4 
6 
Fmoc-L-naphthylalanine (236 mg, 0.54 mmol), PyBOP 
(281 mg, 0.54 mmol), HOBT (137 mg, 0.54 mmol), and 
 DIPEA (0.19 mL) dissolved in DMF (6 mL) 
16 
 
• Washing after coupling: The resin was washed with DMF, CH2Cl2, MeOH, and 
DMF (5 × 10 mL each), the solvents drained, and the resin dried in vacuum.  
• Washing before cleavage: The resin was washed with DMF, CH2Cl2, MeOH, and 
Et2O (5 × 10 mL each), the solvent drained and the resin dried in vacuum. Fmoc-8-
mer peptide-bound resin (270 mg) was obtained. A part of the resin (70 mg) was 
taken out before deprotection. 
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• Deprotection: The remaining resin (200 mg) was treated with 25% piperidine/ 
DMF (10 mL) for 30 min. 
• Cleavage: Fmoc-protected and Fmoc-deprotected peptide-bound resins were 
cleaved according to the same procedure. The Fmoc-protected resin was treated 
with TFA (1.75 mL) and H2O (0.10 mL). The suspension was stirred in an ice-bath 
for 30 min and at rt for an additional two hours. The Fmoc-deprotected resin was 
treated with TFA (4.75 mL) and H2O (0.25 mL). The suspension was stirred in an 
ice-bath for 30 min and at rt for an additional two hours. The resin was separated 
on a sintered funnel and then washed twice with a small amount of TFA. The 
filtrate was evaporated to dryness (< 50 °C). Cold Et2O was added into the residue, 
and the mixture was stored in a refrigerator overnight. The solvent was removed 
by centrifugation to give a white precipitate, which was dried in vacuum (20 mg 
for Fmoc-protected peptide and 90 mg for Fmoc-deprotected peptide). 
• For the N-deprotected-peptide, ES-MS calcd for C48H59N8O10 [M + 1]+ 907.4, 
found 907.2.  For the N-Fmoc protected-peptide, no molecular ion peak or any 
fragment peak was identified (calcd for C63H69N8O12 [M + 1]+ 1129.50). 
 
4. 6. 3 8-Mer bichromophoric peptide by Fmoc-strategy solid-phase peptide 
synthesis (28, H-Aib-Car-Aib-Phe-Aib-Bpa-Aib-Phe-OH) 
• Swelling: Fmoc-Phe-Wang resin (0.35 g, 0.224 mmol) was swollen in DMF (5 
mL) for 1 hour, and drained the solvents. 
• Deprotection: The resin was treated with 25% piperidine in DMF (5 mL) with N2 
bubbling for 30 min, twice. A positive Kaiser test indicated the presence of a 
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primary amines and positive TBNS (orange beads) or chloranil test indicated a 
primary amines with a highly-hindered Aib unit, especially. 
• Washing: The resin was washed with DMF, CH2Cl2, and DMF (5 × 10 mL each), 
drained the solvents and the resin dried in vacuum. 
• Activation and coupling: The coupling reagents (listed in Table 4.3) were mixed in 
a round flask and stirred for 5 min, and then added to the resin with N2 bubbling 
for the indicated period. Negative Kaiser, TBNS or chloranil tests signaled 
complete coupling. 
 
Table 4-3   The quantities of coupling reagents and reaction times for synthesis of 8-Mer bichromophoric 
peptide (28). 
 
Step Coupling reagents Reaction time (hr) 
1, 3, 5, 7 
Fmoc-α-aminoisobutyric acid (364 mg, 1.12 mmol), PyBOP 
(582 mg, 1.12 mmol), HOBT (170 mg, 1.12 mmol), and  
DIPEA (0.4 mL) dissolved in DMF (7.5 mL) 
6 
2 
Fmoc-4-benzoyl-L-phenylalanine (329 mg, 0.67 mmol), PyBOP 
(348 mg, 0.67mmol), HOBT (102 mg, 0.67 mmol), and  
DIPEA (0.25 mL) dissolved in DMF (4.5 mL) 
16 
4 
Fmoc-D-phenylalanine (434mg, 1.12 mmol), PyBOP (582 mg, 
1.12 mmol), HOBT (170 mg, 1.12 mmol), and  
DIPEA (0.4 mL) dissolved in DMF (7.5 mL) 
12 
6 
N-Fmoc-3-(N’ -ethyl-3-carbazolyl)-L-alanine (283 mg, 0.56 
mmol), PyBOP (291 mg, 0.56 mmol), HOAT (85 mg, 0.56 mmol), 
and DIPEA (0.2 mL) dissolved in DMF (4 mL) 
18 
 
• Washing: The resin was washed with DMF, CH2Cl2, MeOH and DMF (5 × 10 mL 
each), drained the solvents and the resin dried in vacuum.  
• Final washing: The resin was washed with DMF, CH2Cl2, MeOH, and Et2O (5 × 
10 mL each), drained the solvents and the resin dried in vacuum. 
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• Cleavage: The dry resin (0.3 g) was treated with a solution of TFA/H2O/ 
triisopropylsilane (95: 2.5: 2.5, 8 mL). The suspension was stirred at an ice-bath 
for 30 min and at rt for an additional three hours. The resin was separated on a 
sintered funnel, and washed with a small amount of TFA, twice. The filtrate was 
evaporated to dryness (< 50 oC). The cold Et2O was added into the residue, and a 
white precipitate formed. The mixture was stored in a refrigerator overnight. The 
solvent was removed by centrifugation and the white solid was dried in vacuum 
(150 mg, 60%). ES-MS calcd for C67H78N9O10 [M + 1]+ 1168.6, found 1168.8. 
 
4. 6. 4 Cyclization in solution (29, cyclo(Aib-Car-Aib-Phe-Aib-Bpa-Aib-Phe)) 
 
The linear peptide 28 (100 mg, 0.086 mmol) was dissolved in DMF (15 ml). A solution 
including HATU (43 mg, 0.11 mmol) and HOAt (16 mg, 0.11 mmol) in DMF (2 mL) 
was added with stirring under N2. The mixture was cooled to 0 °C. DIPEA (0.15 mL) was 
added dropwise. The color of the solution changed from colorless to yellow. The progress 
of the reaction was followed by normal-phase TLC (CHCl3/MeOH 10:1). After being 
stirred overnight, the reaction was quenched with a small amount of H2O. Aq. Na2CO3 
(5%, 60 mL) was added, and then EtOAc was used to extract the desired product (3 × 100 
mL). The combined organic phase was washed with brine, KHSO4 (3 × 20 mL) and 
brine. The solvent was dried over Na2SO4 and removed on a rotary evaporator to give an 
oily residue. It was dissolved in CHCl3, and then the solvent was removed. Cold Et2O 
was added slowly and the mixture was stored in the refrigerator overnight for 
crystallization. After removal of the solvent by centrifugation, a semitransparent solid, 
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cyclo(Aib-Car-Aib-Phe-Aib-Bpa-Aib-Phe, was obtained (70 mg, 70%). ES-MS calcd for 
C67H76N9O9 [M + 1]+ 1150.6, found 1150.8, 1172.8 [M + Na]+. 
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Chapter 5   Summary 
 
1. The Sorensen method was adopted to synthesize N-Ac (or Boc)-3-(9-anthryl)-DL-
alanine methyl ester. 
2. Erlenmeyer’s azlactone method was found to be unsuitable for the synthesis of 3 -
(N-ethyl-3-carbazolyl)-DL-alanine due to sensitivity of the carbazole ring to 
strong acids and electrophilic reagents. N-Ac (or N-Boc)-3-(N’ -ethyl-3-
carbazolyl)-DL-alanine methyl ester was successfully obtained by a Wittig-
Horner reaction under mild conditions. 
3. Dual enzymatic hydrolysis was adopted to obtain amino acids with high 
enantiomeric purity. 
• ChiroCLEC-BL was used to selectively remove the methyl group from L-
amino acid methyl esters. N-acetyl-3-(N’ -ethyl-3-carbazolyl)-L-alanine was 
completely hydrolyzed in acetone-phosphate buffer at 37 °C after 24 hr; these 
conditions didn’t work for N -acetyl-3-(9-anthryl)-L-alanine methyl ester and 
their Boc derivatives. A 40% of conversion for this resolution was obtained 
in DMF-phosphate buffer at 60 °C for 72 hr only for N-Ac-3-(9-anthryl)-L-
alanine methyl ester.  But this enzyme doesn’t work well for their Boc 
derivatives. 
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• Amanoacylase was used to remove the acetyl groups. Complete deacylation 
was achieved after 24 hr for N-acetyl-3-(N’ -ethyl-3-carbazolyl)-L-alanine 
and 48 hr for N-acetyl-3-(9-anthryl)-L-alanine, both at 37 °C. 
4. The 8-mer linear peptide (H-Aib-Car-Aib-Phe-Bpa-Aib-Phe-OH) was effectively 
synthesized via Fmoc-strategy solid-phase peptide synthesis, and its 
corresponding cyclic peptide was obtained in solution. ES-MS confirmed the 
molecular weights of all target compounds. 
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Chapter 6   Future Work 
 
Possible future work could include the following investigations. 
1. The photophysics of the target linear peptide and its corresponding cyclic peptide. 
Absorption, fluorescence, and phosphorescence spectroscopy, and laser flash 
photolysis could be studied to determine the pathway of the intramolecular energy 
transfer and its efficiency.   
2. X-ray analysis of the target peptides could be used to determine their conformations.  
3. IR analyses of the target peptides can be used to study their hydrogen-bonding 
interactions.  
4. Based on the above experimental results, computational chemistry studies could be 
used to seek good calculational models and design novel peptide-based nanotubes 
with desirable properties.   
5. Another set of linear and cyclic peptides incorporating a different chromophore, H-
D-Ala-Car-D-Ala-Phe-D-Ala-Bpa-D-Ala and cyclo(D-Ala-Car-D-Ala-Phe-D-Ala-
Bpa-D-Ala), where Ala is to be replaced by Aib, would be synthesized. This cyclic 
compound would be expected to self-assemble into nanotubes.  
6. Another new bichromophoric peptide pair, including anthracene and benzophenone, 
would be synthesized to make a contrasting investigation in search of the high-
performance molecular wire.  
7. Changing the attachment position of the bichromophores can be used to study the 
influence of distance between the chromophores on intramolecular energy transfer. 
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9-Chloromethylanthracene (NMR-1) 
  
 97 
Diethyl 9-anthrylmethylacetamidomalonate (NMR-2) 
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N-Acetyl-3-(9-anthryl)-DL-alanine (NMR-3) 
 
 
 
  
 99 
N-Acetyl-3-(9-anthryl)-DL-alanine methyl ester (NMR-4) 
 
 
  
 100 
N-Acetyl-3-(9-anthryl)-DL-alanine methyl ester (NMR-5) 
 
 
 
  
 101 
N-Acetyl-3-(9-anthryl)-DL-alanine methyl ester (after  enzymatic hydrolysis, NMR-6) 
 
 
 
  
 102 
N-Acetyl-3-(9-anthryl)-L-alanine with N-acetyl-3-(9-anthryl)-DL-alanine methyl ester (NMR-7) 
 
 
 
  
 103 
N-Acetyl-3-(9-anthryl)-DL-alanine methyl ester (with chiral reagent, NMR-8) 
 
 
 
  
 104 
N-Acetyl-3-(9-anthryl)-L-alanine (NMR-9) 
 
 
 
  
 105 
N-Acetyl-3-(9-anthryl)-DL-alanine (NMR-10) 
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N-t-Butyloxycarbonyl-3-(9-anthryl)-L-alanine (NMR-11) 
 
 
  
 107 
N-t-Butyloxycarbonyl-3-(9-anthryl)-L-alanine (NMR-12) 
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Diethyl 9-anthrylmethyl-N-(t-butyloxycarbonyl)aminomalonate (NMR-13) 
 
 
 
  
 109 
Diethyl 9-anthrylmethyl-N-(t-butyloxycarbonyl)aminomalonate (NMR-14) 
 
 
 
  
 110 
3-(9-Anthryl)-DL-alanine methyl ester (NMR-15) 
 
 
  
 111 
N-t-Butyloxycarbonyl-3-(9-anthryl)-DL-alanine methyl ester (NMR-16) 
 
 
 
  
 112 
N-Ethyl-3-hydroxymethyl carbazole (NMR-17) 
 
 
 
  
 113 
4-(3-(N-Ethylcarbazolylidene))-2-phenyloxazol-5-one (NMR-18) 
 
 
  
 114 
N-Benzoyl-3-(N’-ethyl-3-carbazolyl)acrylic acid (NMR-19) 
 
 
  
 115 
N-Benzoyl-3-(N’-ethyl-3-carbazolyl)alanine (NMR-20) 
 
 
  
 116 
Methyl 2-(t-butoxycarbonylamino)-2-(dimethoxyphosphonyl)acetate (NMR-21) 
 
 
  
 117 
Methyl 2-(t-butoxycarbonylamino)-2-(dimethoxyphosphonyl)acetate (NMR-22) 
 
 
 
  
 118 
Methyl 2-acetamino-2-(dimethoxyphosphonyl)acetate (NMR-23) 
 
 
 
  
 119 
Methyl 2-acetamino-2-(dimethoxyphosphonyl)acetate (NMR-24) 
 
 
 
  
 120 
N-t-Butoxycarbonyl-3-(N’-ethyl-3-carbazolyl)-DL-acryl acid methyl ester (NMR-25) 
 
 
 
  
 121 
N-Acetyl-3-(N’-ethyl-3-carbazolyl)-DL-acrylic acid methyl ester (NMR-26) 
 
 
 
  
 122 
N-Acetyl-3-(N’-ethyl-3-carbazolyl)-DL-acrylic acid methyl ester (NMR-27) 
 
 
  
 123 
N-t-Butoxycarbonyl-3-(N’-ethyl-3-carbazolyl)-DL-alanine methyl ester (NMR-28) 
 
 
  
 124 
N-Acetyl-3-(N’-ethyl-3-carbazolyl)-DL-alanine methyl ester (NMR-29) 
 
 
  
 125 
N-Acetyl-3-(N’-ethyl-3-carbazolyl)-DL-alanine methyl ester (NMR-30) 
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N-t-Butoxycarbonyl-3-(N’-ethyl-3-carbazolyl)-L-alanine (NMR-31) 
 
 
  
 127 
N-t-Butoxycarbonyl-3-(N’-ethyl-3-carbazolyl)-L-alanine (NMR-32) 
 
 
  
 128 
3-(N-Ethyl-3-carbazolyl)-L-alanine (NMR-33) 
 
 
  
 129 
3-(N-Ethyl-3-carbazolyl)-L-alanine (NMR-34) 
 
 
  
 130 
N-Fmoc-3-(N’-ethyl-3-carbazolyl)-L-alanine (NMR-35) 
 
 
  
 131 
N-Fmoc-3-(N’-ethyl-3-carbazolyl)-L-alanine (NMR-36) 
 
 
  
 132 
H-Aib-Car-Aib-Phe-Aib-Bpa-Aib-Phe-OH (NMR-37) 
 
 
  
 133 
cyclo(Aib-Car-Aib-Phe-Aib-Bpa-Aib-Phe) (NMR-38) 
 
 
  
 134 
3-(N-Ethyl-3-carbazolyl)-L-alanine (MS-1) 
 
 
  
 135 
N-Fmoc-3-(N’-ethyl-3-carbazolyl)-L-alanine (MS-2) 
 
 
 
  
 136 
H-Car-D-Ala-Bpa-D-Ala-OH (MS-3) 
 
 
  
 137 
H-D-Ala-Nap-D-MeAla-Ala-D-Ala-Bpa-D-Ala-Ala-OH (MS-4) 
 
 
 
  
 138 
H-Aib-Car-Aib-Phe-Aib-Bpa-Aib-Phe-OH (MS-5) 
 
 
 
  
 139 
cyclo(Aib-Car-Aib-Phe-Aib-Bpa-Aib-Phe) (MS-6) 
 
 
  
 140 
H-D-Ala-Nap-D-MeAla-Ala-D-Ala-Bpa-D-Ala-Ala-OH (MS-7) 
 
 
  
 141 
H-Aib-Car-Aib-Phe-Aib-Bpa-Aib-Phe-OH (MS-8) 
 
 
 
  
 142 
cyclo(Aib-Car-Aib-Phe-Aib-Bpa-Aib-Phe) (MS-9) 
 
 
